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ABSTRACT
BACKGROUND:
A comparative study of fetomaternal outcome in a patients with severe pre-
eclampsia and eclampsia with HELLP syndrome and without HELLP Syndrome.
Purpose: To determine the trend of occurrence of HELLP syndrome, risk factors,
its complications and its effect on maternal and perinatal outcome of HELLP
syndrome in pregnant women at Tirunelveli Medical College Hospital, Tirunelveli.
METHODS:
Patients with severe hypertension in pregnancy who were admitted between
Feb2015 to July 2015 at Tirunelveli Medical College Hospital, Tirunelveli.. Out of
100 cases if severe preeclampsia/eclampsia, there were 43 cases of HELLP
syndrome. These were compared with case without HELLP syndrome for their
mode of presentation along with maternal and perinatal morbidity and mortality.
RESULT:
The overall incidence of HELLP syndrome was 0.4% in the antepartum
factors; class V SES, multi (55.8% Vs 33.3%, p<0.05), preeclampsia (90% Vs
73.7%, p<0.05), symptoms (81.4% vs 61.4%, p<0.05), Haemolysis (86% vs 3.5%
p<0.05), ARF (16.2% vs 3.5% p<0.05) were statistically significant. Inthe
intrapartum factors there were no significant differences between the two groups in
mode of delivery. Abnormal perinatal outcome was (54.5% vs 24.6% p<0.001).
Conclusion:
Women with severe hypertension in pregnancy manifesting with HELLP
syndrome show a significantly greater frequency of developing Abruption, ARF
and DIC. Therefore, their care necessitates intensive monitoring to preclude
development of these complications. Successful management requires recognition,
a timely intervention and to render optimal patient treatment.
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INTRODUCTION 
Every woman wishes to have a healthy pregnancy which culminates in a 
healthy baby and a healthy mother. Unfortunately, some women develop dreaded 
complications that may result in adverse obstetric outcomes. These include 
Pregnancy induced hypertension, Pre-eclampsia, Eclampsia and HELLP 
syndrome. 
Pre-eclampasia occurs in 5-10% of pregnancies. The HELLP syndrome 
(haemolysis, elevated liver enzymes, and low platelets) in a variant of severe pre-
eclampsia that is associated with significant maternal and perinatal morbidity and 
mortality. HELLP syndrome develops in 6-12% of women with preeclampsia or 
eclampsia accounting for 0.4-0.7% of all pregnancies. 
Maternal mortality is due to consequences such as pulmonary oedema, 
renal failure, disseminated intravascular coagulation and subcapsular liver 
hematoma. Perinatal mortality appears to be primarily related to the gestational 
age at the time of delivery. HELLP syndrome is regarded as a higher risk for the 
mother and neonate compared to pre-eclampsia. 
As our hospital provides treatment facilities to large number of Pre-
eclampsia, eclampsia and a relatively higher number of patients of HELLP 
syndrome, we have the opportunity to conduct such studies which can help us to 
determine the trend of occurrence of HELLP syndrome, its complications and its 
effect on maternal and fetal outcome. This will help us in understanding better 
about the pathophysiology of the disease which can be applied to improve the 
management and thereby improve the maternal and perinatal outcome.  
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AIM OF THE STUDY 
A comparative study of fetomaternal outcome in a patients with severe 
pre-eclampsia and eclampsia with HELLP syndrome and without HELLP 
Syndrome. 
 To determine the trend of occurrence of HELLP syndrome, risk factors, 
its complications and its effect on maternal and perinatal outcome of HELLP 
syndrome in pregnant women at Tirunelveli Medical College Hospital, 
Tirunelveli. 
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS OF HELLP SYNDROME 
 In the year 1954 Prichard et al and Chesley (1978) described that pre 
eclamptic patient are more prone to developed haemolysis, hepatic dysfunction 
and low platelets1,3. But the acronym HELLP Syndrome was coined by Louis 
Weinstein 1982 (hemolysis, elevated liver enzymes and low platelets) that 
clinicians could more easily recognise.6  
Goodlin considered it an early form of severe preeclampsia and labelled as 
a great imitator, impending gestosis, EPH (edema, proteinuria, hypertension), 
Gestosis type B and extended toxemia syndrome.4,5 Weinstein considered it an 
unique variant of preeclampsia,6 while Mackenna and Colleagues considered it as 
misdiagnosed preeclampsia.7 
CLASSIFICATION OF HYPERTENSIVE DISORDER IN PREGNANCY  
According to NHBPEP- National High Blood Pressure Education Program 
(2000) hypertensive disorder in pregnancy is classified as  
1. GESTATIONAL HYPERTENSION: 
 New onset hypertension after 20 weeks of pregnancy 
 Systolic BP ≥140 or diastolic BP≥90mm Hg for first time during pregnancy 
 No proteinuria 
 BP returns to normal before 12 weeks postpartum 
 Final diagnosis made only postpartum 
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2. PREECLAMPSIA: 
MILD PREECLAMPSIA 
 BP≥140/90mm Hg after 20 weeks gestation 
 Proteinuria≥300 mg/24 hours or ≥1+dipstick 
SEVERE PREECLAMPSIA: 
 BP ≥160/110mm Hg 
 Proteinuria 2.0g/24 hours or ≥2+ dipstick 
 Serum creatinine > 1.2mg/dl unless known to be previous elevated 
 Platelets < 100,000/µL 
 Microangiopathic hemolysis-increased LDH 
 Elevated serum transaminase levels- ALT or AST 
 Persistent headache or other cerebral or visual disturbance 
 Persistent epigastric pain 
3. ECLAMPSIA: 
 Seizures that cannot be attributed to other causes in a women with 
preeclampsia 
4. SUPERIMPOSED PREECLAMPSIA ON CHRONIC 
HYPERETENSION: 
 New-onset proteinuria ≥ 300mg/24 hours in hypertensive women but no 
proteinuria before 20 weeks gestation 
 A sudden increase in proteinuria or blood pressure or platelet count < 
100,000/µL in women with hypertension and proteinuria before 20 weeks 
gestation 
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5. CHRONIC HYPERTENSION: 
 BP ≥ 140/90mm Hg before pregnancy or diagnosed before 20 weeks 
gestation 
or 
 Hypertension persistent after 12 weeks postpartum 
INCIDENCE OF PREECLAMPSIA 
 6-15% in multipara 
 2-4% in multipara77 
RISK FACTORS FOR PRE-ECLAMPSIA, sibai BM, lancet 2005 
 Age > 35 years 
 Parity 
 Interval from last pregnancy > 10years 
 Obstetric factors 
o preeclampsia or gestational hypertension in prior pregnancy 
o Multiple gestation 
o Hydatidiform mole 
o Hydrops fetails 
o Abnormal uterine artery Doppler at 18-24 weeks 
 Family history of pre-eclampsia 
 pre-existing medical disorders 
o Hypertension 
o Diabetes melitius 
o Obesity (BMI of 35kg/m2 or more) 
6 
o Renal disease 
o vascular disease 
o Autoimmune disease 
o Thrombophilias 
 Couple-related risk factors34 
o Primipaternity 
o Limited sperm exposure 
o Pregnancies after donor insemination; oocyte donation; embryo 
donation 
o Protective effect of “partner change” in case of previous 
preeclamptic pregnancy 
o “Dangerous male partner” (paternal effects) 
ETIO PATHOGENESIS OF PREECLAMPSIA  
 Increased risk of preeclampsia in women exposed to chorionic villi for first 
time. 
 Hyperplacentosis (abundance of chorionic villi-twins, mole) 
 Genetic predisposition  
 Abnormal trophoblast invasion  
 Immunological maladaptation to inflammatory changes. 
 Calcium and magnesium deficiency68  
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PLACENTAL 
HYPOPERFUSION 
SEMINAL CYTOKINES (TGF, IFN) 
DANGEROUS FATHER-other 
determinants 
PATERNAL HLA-C 
LENGTH AND TYPE OF 
SPERM EXPOSURE 
ETIOLOGY AND PATHOGENESIS 
OF PREECLAMPSIA 
COUPLE SPECIFIC 
IMMUNE 
MALADAPTATION 
DISTURBED INTERACTION 
DECIDUAL NATURAL KILLER CELLS 
AND HLA-C, G AND E ON INVASIVE 
CYTOTROPHOBLAST 
INCREASED 
APOPTOSIS 
TROPHOBLAST CELLS 
Free radicals 
IMPAIRED REMODELING 
SPIRAL ARTERIES 
ENDOTHELIAL CELL 
ACTIVATION 
Susceptibility genes 
Thrombophilias 
Obesity 
Insulin resistance 
Infections 
Smoking( risk reduction) 
 
INCREASED 
LEVELS SOLUBLE 
VEGF RECEPTOR 
HYPERTENSIVE 
INFLAMMATORY 
MATERNAL 
RESPONSE 
SYNDROME 
PREECLAMPSIA 
FETAL SYNDROME 
IUGR, PRETERM BIRTH 
FETAL DEMISE 
Deficient vascular priming: INF, angiopoietin-2, VEGF, PLGF 
Adverse decidual cytokine milieu (Type 1 dominance over Type 2) 
FAS- FAS LIGAND Impaired interstitial and endovascular cytotrophoblast invasion 
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9 
CLINICAL FEATURES  
 Severe Head ache  
 Vomiting  
 Epigastric pain 
 Visual disturbances 
 Papilledema  
 Oliguria  
 Thrombocytopenia edema  
 HELLP Syndrome  
INVESTIGATIONS 
 Urine analysis proteinuria. 
 Hb-raised(Hemoconcentration, except in hemolysis) 
 Platelet-low. 
 Peripheral smear-shistiocytes. 
 INR and APTT-higher in DIC. 
 Serum creatinine – higher 
 ALT, AST, LDH-higher 
 Albumin-lower 
 Bilirubin – higher. 
 FUNDUS examination. 
  
10 
PREDICTIVE TESTS FOR DEVELOPMENT OF THE PREECLAMPSIA 
Conde – Agudelo & Associates,2009. 
PLACENTAL PERFUSION/ VASCULAR RESISTANCE 
Roll-over test, isometric handgrip or cold pressor test, angiotensin-II 
infusion, midtrimester mean arterial pressure, platelet angiotensin-II binding, 
rennin, 24-hour ambulatory blood pressure monitoring, uterine artery or fetal 
transcranial Doppler velocimetry 
FETEL-PLACENTAL UNIT ENDOCRINE DYSFUNCTION 
Human chronic gonadotropin (hCG), alpha-fetoprotein (AFP), estriol, 
pregnancy associated protein A (PAPP A), inhibin A, activin A, placental protein 
13, corticotrophin releasing hormone 
RENAL DYSFUNCTION 
 Serum uric acid, microalbuminuria, urinary calcium or kallikrein, 
microtransferrinuria, N-acetyl-β-glucosaminidase 
ENDOTHELIAL DYSFUNCTION/ OXIDANT STRESS 
Platelet count and activation, fibronectin, endothelial adhesion molecules, 
prostaglandin, thromboxane, C-reactive protein, cytokines, endothelin, neurokinin 
B, homocysteine, lipids, antiphospholipid antibodies, plasminogen activator-
inhibitor (PAI), leptin, p-selectin, angiogenic factors to include placental growth 
factor (PIGF), vascular endothelial growth factor (VEGF). fms-like tyrosine 
kinase receptor-1 (sFIt-1), endoglin68 
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OTHERS/MISCELLANEOUS 
Antithrombin-III (AT-3), atrial natriuretic peptide (ANP), β2 -
microglobulin, genetic markers, free fetal DNA, serum proteonomic markers 
MANAGEMENT 
 
 
 
 
 
 
 
 
 
 
 
NO 
 
 
 
 
 
 
 
Pre-eclampsia 
Maternal and fetal 
assessment 
Gestational age ≥ 38 weeks 
At ≥34 weeks gestation: 
 Severe pre-eclampsia 
 Labor or rupture of membrane 
 Abnormal fetal testing 
 Severe oligohydramnios or 
 Fetal growth restriction 
Deliver 
< 23 weeks Severe disease Mild disease 
Hospital or office 
management 
Maternal and fetal 
assessment 
22 – 32 
weeks 
33 – 34 
weeks 
Worsening 
maternal or fetal 
condition 
≥38 weeks 
Labor or rupture of 
membranes 
Steroids 
Antihypertensives 
Daily assessment of 
maternal-fetal 
conditions 
Delivery at 34 
weeks. 
Steroids 
Delivery after 48h 
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TIMING FOR DELIVERY (ACOG, 2010) 
 38-39 weeks of gestation for women not requiring medication. 
 37-39 weeks for women with controlled hypertension with medication. 
 36-37 weeks with severe hypertension. 
 HYPITAT (Hypertension and Preeclampisa Intervention Trial At Term) 
(Koopmans et al, 2009) shows the outcome of pregnancy with gestational 
HT induced at >37 weeks was better compared to expectant 
management17. 
INDICATIONS FOR DELIVERY WITH EARLY-ONSET SEVERE 
PREECLAMPSIA FROM SIBAI AND BARTON (2007). 
I. MATERNAL 
1. Persistent severe headache or visual changes;  
2. Pulmonary edema SaO2< 94% 
3. Uncontrolled severe hypertension despite treatment  
4. Oliguria < 500 ml/24 hr or serum creatinine ≥ 1.5 mg/dL 
5. Persistent platelet counts<100,000/µL 
6. Suspected abruption. 
II. FETAL 
1. Severe growth restriction - < 5th percentile for EGA 
2. Persistent severe oligohydramnios – AFI < 5cm 
3. Biophysical profile ≤ 4 done 6 hr apart 
4. Reversed end-diastolic umbilical artery flow 
5. Fetal death 
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CONTROL OF BLOOD PRESSURE  
CHOICE OF DRUGS  
NICE,2010 recommends Labetalol is the first line of drug29. It can be given 
both orally and intravenously. Due to beta receptor blocking activity, it is better to 
avoid in asthmatic. Labetalol causes neonatal hypoglycaemia and bradycardia. 
OTHER DRUGS IN USE ARE 
 Nifedepine 
 Hydralazine 
 Avoid sublingual nifedepine to reduce BP in patient with volume 
depletion, since it will cause percipitious fall in BP (NICE, 2010). 
 Antidote for Mgso4 toxicity is 10 g of 10% calcium gluconate given IV. 
 Labetalol 20mg IV bolus followed by 40 mg if not effective within 10 
minutes then, 80mg every 10 mins, max dose 220mg. 
 Nifedepine-10mg orally every 30 mins, max of 3 doses. 
 Hydralazine 5-10mg IV every 15-20 minutes  
SEIZURE PREVENTION  
Magnesium sulfate dosage schedule dosage schedule for severe preeclampsia 
and eclampsia 
Continuous intravenous infusion, frederick P.Zuspan,MD., 
1. Give 4- to 6-g loading dose of magnesium sulfate diluted in 100mL of IV 
fluid administered over 15-20 min54,68 
2. Begin 2g/hr in 100mL of IV maintenance infusion. Some recommend 1g/hr 
3. Monitor for magnesium toxicity: 
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a. Assess deep tendon reflexes periodically 
b. Urinary output. 
c. Respiratory rate.   
4. Magnesium sulfate is discontinued 24 hr after delivery 
Intermittent Intramuscular Injections (Pritchard Regimen) 
1. Give 4g of magnesium sulfate (MgSO4·7H2O USP) as a 20% solution 
intravenously at a rate not to exceed 1g/min 
2. Followed by 10 g of 50% magnesium sulfate solution, one-half (5g) 
injected deeply in the upper outer quadrant of both buttocks through a 3-
inch-long 20-gauage needle. (Addition of 1.0mL of 2% lidocaine 
minimizes discomfort). If convulsions persist after 15 min, give up to 2g 
more intravenously as a 20% solution at a rate not to exceed 1g/min. 
3.  Every 4 hr thereafter give 5g of a 50% solution of magnesium sulfate 
injected deeply in the upper outer quadrant of alternate buttocks, but only 
after ensuring that: 
a. The patellar reflex is present 
b. Respirations are not depressed, and 
c. Urine output the previous 4hr exceed 100mL 
4. Magnesium sulfate is discontinued 24 hr after delivery 
COMPLICATION 
MATERNAL COMPLICATIONS OF SEVERE PREECLAMPSIA 
RESPIRATORY SYSTEM 
 Pulmonary edema 2-5% 
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CNS 
 Eclampsia <1%. 
 Hemorrhage. 
 Cortical blindness. 
 Retinal blindness. 
 Raised ICT. 
 Encephalopathy. 
RENAL SYSTEM 
 Cortical necrosis  
 Renal tubular necrosis 1-5% 
CVS 
 Left ventricular failure 
 Aortic dissection 
LIVER 
 HELLP syndrome 10-20%  
 Subcapsular hematoma <1% 
COAGULATION SYSTEM 
 DIC 
 Hemorrhage 
MULTIPLE ORGANS 
 MODS 
 Death 
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HELLP SYNDROME 
INCIDENCE OF HELLP SYNDROME  
Overall incidence of HELLP Syndrome is one in thousand pregnancies 
incidence in pre eclamtic and eclamptic is 4 to 12 percentage78. 30 percentage 
occur in postpartum period 70 percentage occurs in antepartum period in the 
third trimester and often associated in caucasian multiparous women aged 
about 25 years.  Of the two thirds of women who are first diagnosed with 
HELLP syndrome antepartum, 10% will be identified before 27 weeks, 20% in 
pregnancies beyond 37 weeks, and the majority 70% occurring between 27 and 
37 weeks gestation.  
PATHOPHYSIOLOGY    HELLP SYNDROME  
Etiology is unknown release of vaso constrictor vaso active amine, deficiency 
of platelet activating factor inhibitor, pathogenesis of HELLP syndrome is 
associated with factor V R 500 Q mutation (Brenner et al. 1996) Activated 
Protein C resistance resulting from mutation in coagulation factor V has 
recently emerged as the leading cause of thrombosis44. 
Patients with pure preeclampsia and HELLP Syndrome will have 
significantly higher level of serum C-erb B-2 encoded oncoprotein fragment 
P105 (Meden et al. 1997)50 
Lower beta B-subunit Inhibin production in extra villous trophoblast 
cells in HELLP syndrome demonstrates that this subunit might have an 
important role in the pathogenesis of HELLP syndrome52. 
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PATHOPHYSIOLOGY    HELLP SYNDROME 
 
        
Etiology: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unknown 
Disordered Immunological 
Process 
Sudden release of Fetal & 
Placental Cell 
Vaso contriction 
Vascular Repair Deficiency 
Release of vaso constrictor vaso 
active amine  
Deficiency of platelet activating 
factor inhibitor  
Injury to the Vascular 
Endothelium 
Aggregation of platelet  
Activation of platelet  
Increase in beta thrombomodulin 
(Consumption)  
 
Fibrin activation  
Fibrin deposits in Hepatic 
sinusoids  
Selective Organ Ischemia 
 
Various Symptomatology 
(Headache, blurring of vision, 
Oliguria, epigastric pain) 
Renal 
Transient elevation 
of serum creatinine 
to ARF which may 
recover or lead to 
permanent cortical 
necrosis 
 
Hepatic  
Periportal or focal 
parenchymal 
necrosis with 
hyaline deposits in 
the sinusoid due to 
fibrin deposit may 
lead to hepatic 
infarction and sub 
capsular haematoma    
Platelet 
The life span of 
platelet is reduced in 
pre eclamptic 
patient to 3 to 5 days 
and this span is 
further reduced in 
HELLP Syndrome 
due Platelet 
aggregation & 
Consumption 
 
RBC  
RBC become 
fragmented when 
they pass through 
damaged small 
vessel endothelium 
resulting in micro 
angio pathic 
haemolysis. It does 
not correlate to 
degree of organ 
damage  
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Thrombocytopenia with eclampsia has been described at least since 1922 
by Stancke. Because it is common, the platelet count is routinely measured in 
women with any form of gestational hypertension. The frequency and intensity of 
thrombocytopenia vary and are dependent on the severity and duration of the 
preeclampsia syndrome as well as the frequency with which platelet counts are 
performed (Heilmann and colleagues, 2007; Hupuczi and co-workers, 2007). 
Overt thrombocytopenia- defined by a platelet count < 100,000/µL- indicates 
severe disease. In general, the lower the platelet count, the higher the rates of 
maternal and fetal morbidity and mortality (Leduc and co-workers, 1992). In most 
cases, delivery is advisable because thrombocytopenia usually continues to 
worsen. After delivery, the platelet count may continue to decrease from the first 
day. It then usually increases progressively to reach a normal level within 3 to 5 
days. With HELLP syndrome, the platelet count continues to raise after delivery. 
In some women whose platelet counts do not nadir until 48 to 72 hours, other 
causes of thrombocytotenia should be considered. 
IMMUNOLOGY OF HELLP SYNDROME 
Pre eclampsia has been considered for a number of years by many 
investigators to result at least in part, from disordered immunologic processes. 
The studies that support this belief, list the increased incidence in primigravida, 
the increased risk in pregnancies with an increased volume of trophoblastic 
tissue, pregnancy with a new partner, previous use of barrier contraceptive and 
pregnancy after oocyte donation. Since HELLP syndrome appears to be 
atypical form of preeclampsia, it too could result from disordered immunity. 
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Increased plasma levels of anaphylotoxins C3a and C5a have been 
demonstrated in patients with preeclampsia / HELLP syndrome. Depressions 
of both T-cell and B-cell potential and impaired monocyte handling of 
intracellular pathogens have been reported in pregnancies complicated by 
HELLP syndrome. This immune dysfunction preceded the laboratory diagnosis 
of preeclampsia by 7-14 days. 
Haeger et al (1996) suggested that inflammatory mechanisms may 
participate in the pathophysiology of severe preeclampsia since increased 
release of Tumor necrosis factor alpha (TNFα) and interleukin 6 in women with 
HELLP Syndrome41. 
Dudley et al (1996) supported the hypothesis that the regulation of IL-
12 production and metabolism is abnormal in women with preeclampsia and 
HELLP Syndrome, perhaps contributing to the immunologic alterations 
characteristics of these disorders37. 
Antiphospholipid antibodies may play a role in the pathogenesis of 
HELLP syndrome (Nagayama et al 1997)45. 
CLINICAL FEATURES 
Patients with HELLP syndrome may present with various signs and 
symptoms, none of which are diagnostic and all of which be found in patients 
with severe preeclampsia-eclampsia without HELLP syndrome. 
Prodromal Symptoms include (Portis et al., 1997)46 
1. Weakness and fatigue (90%) 
2. Right upper quadrant and/or epigastric pain (90%) 
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3. Nausea and Vomiting (50%) 
4. Headache 
5. Change in vision 
6. Increased tendency to bleed from minor trauma 
7. Jaundice 
8. Diarrhoea 
9. Shoulder or neck pain 
SIGNS 
1. Proteinuria > 2+ (85%) 
2. Hypertension Diastolic Blood Pressure > 100 mm Hg (69%) 
3. Significant weight gain with generalised edema (55%) 
In Weinstein reports (1982/1985) nausea or vomiting and epigastric pain 
were the most common symptoms6. Sibai et al (1990) noted that the commonest 
symptom was epigastric and/or right upper quadrant pain18. Right upper 
quadrant or epigastric pain is used to assess whether the patient is at high risk 
for development of HELLP syndrome. 
There is delay between the onset of symptoms and the fulfillment of 
diagnostic laboratory criteria (Koenen SV et al 2006)55. 
Severe hypertension (systolic blood pressure > 160 mm Hg, diastolic 
blood pressure > 110mm Hg) is not a constant or even a frequent finding in 
HELLP syndrome (Sibai et al 1986)10.  
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Esan et al (1997) reported that HELLP syndrome can occur after a 
normal delivery in a woman whose blood pressure has remained normal 
throughout the antenatal period49. 
Donaldson (1978) reported that some may experience visual 
disturbances. Neurological affection can also result. 
Jaundice is a rare complication and hyperbilirubinemia may result from 
a combination of hemolysis and liver cell necrosis. However it is unusual for 
icterus to be clinically apparent.  
Maternal ascitis is frequently found at Caesarean delivery in 65% of 
patients with HELLP syndrome (Woods et al 1992)22. 
The risk of opportunistic infections may be increased in patients with 
HELLP syndrome, because of generalised (Both B&T Cell) 
immunosuppression and profound decrease in monocyte phagocytic and 
bactericidal activity (Cunningham et al. 1993)25. 
CLASSIFICATION 
 Classification system are of two types based on platelet count and LDH 
level which reflect the senility of disease process and rapidity of recovery from 
HELLP Syndrome  
The Mississippi Triple Class System further classifies the syndrome based on the 
platelet count: Class I < 50 x 〖10〗^6/l and Class II – 50 x 〖10〗^6/l to 100 x 
〖10〗^6/l and Class III- 100 x 〖10〗^6/l to 150 x 〖10〗^6/l. Classes I and II are 
associated with hemolysis (LDH > 600 U/l) and elevated AST(≥70U/l) 
concentration, while class III requires only LDH > 600 U/l and AST ≥40 U/l in 
22 
addition to the specific platelet count61. Class III HELLP syndrome is indicative 
of a clinically significant transition stage or a phase of the HELLP syndrome that 
may progress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sibai proposed strict diagnostic criteria for HELLP syndrome  
1. Intravascular hemolysis diagnosed by abnormal peripheral blood 
smear 
2. Increased serum bilirubin ≥20.5 µmol/l or ≥1.2mg/100ml 
3. Elevated LDH levels (>600 units/l) 
4. Platelet count of < 100.000/microlitre 
Mississippi 3-class (Martin et al) 
THROMBOCYTOPENIA + HAEMOLYSIS + 
HEPATIC DYSFUNCTION 
CLASS 1 :  Platelets < 50,000 /  µL  
LDH > 600 IU/L 
AST and/or ALT > 70 IU/L 
CLASS 2 :  Platelets > 50,000 - < 1,00,000/ µ L 
LDH > 600 IU/L 
AST and/or ALT > 70 IU/L 
CLASS 3 :  > 1,00,000 - < 1,50,000/ µ L 
LDH > 600 IU/L 
AST and/or ALT > 40 IU/L 
All must be present to qualify... 
Tennessee (Memphis) 
COMPLETE or TRUE  
< 1,00,000/µ L Platelets 
LDH > 600 IU/L 
AST > 70 IU/L 
INCOMPLETE or PARTIAL  
Only one or two of above present + severe pre 
celampsia  
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5. Serum AST (SGOT) levels > 70 IU/l 
6. Low serum haptoglobin level  
7. Drop in Hb% level unrelated to blood loss  
OTHER CLASSIFICATIONS OF HELLP SYNDROME 
 Platelet Count AST LDH 
Sibai et al 11 < 1,00,000/mm3 > 70 IU/L > 600 IU/L 
Van Pampus13 < 1,00,000/mm3 > 50 IU/L >600 IU/L 
Visser and 
Wallenburg14 
< 1,00,000mm3 > 30 IU/L * 
DIFFERENTIAL DIAGNOSIS FOR THE HELLP SYNDROME 
 Different types of thrombocytopenia 
o Benign thrombocytopenia of pregnancy 
o Immunologic thrombocytopenia (ITP) 
o Thrombocytopenia due to folate deficiency 
o Systemic lupus erythematosus 
o Antiphospholipid syndrome (SLE) 
o Antiphospholipid syndrome (APS) 
o Thrombotic thrombocytopenic purpura (TTP) 
o Hemolytic uremic syndrome (HUS) 
 Acute fatty liver of pregnancy 
 Infectious and inflammatory disease 
o Urinary tract infections 
o Acute pancreatitis 
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o Gastritis and gastric ulcers 
o Cholecystitis or cholangitis 
o Hepatitis 
 Pyelonephritis and glomerulonephritis 
 Hyperemesis gravidarum 
 Kidney stones 
 Hemorrhagic or septic shock 
 Disseminated herpes simplex 
 Acute renal failure with acute tubular necrosis 
 Acute cocaine intoxication  
 Pheochromocytoma 
 Intrahepatic cholestasis 
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) & 
HEMOLYTIC UREMIC SYNDROME (HUS) 
 Renal abnormality is more severe  
 Liver enzymes are usually normal  
 Present during post partum period  
 Severe anaemia is present  
ACUTE FATTY LIVER OF PREGNANCY 
 Liver enzymes are elevated but less than 1000  
 Renal abnormality may be present  
 Hypertension and proteinuria are absent  
 Direct bilirubin is elevated  
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INTRA HEPATIC CHOLESTASIS  
 Liver enzymes are elevated but less than 500  
 No Renal abnormality 
 Intense pruritis is present  
VIRAL HEPATITIS  
 Liver enzymes are elevated  
 No Renal abnormality 
 Abnormal serology  
LABORATORY DIAGNOSIS 
The diagnosis of HELLP Syndrome is based on laboratory values of 
Hemolysis liver dysfunction and low platelet in a patient with preeclampsia. 
Liver biopsy is considered as a gold stand for diagnosis but rarely needed 
because of hazardous laboratory work up includes complete blood count 
coagulation profile, serum creatinine, urinary protein, blood urea, serum uric 
acid, pheripheral blood smear and liver function test. 
During disease progression thrombocytopenia occurs first and 
hemolysis occurs last. There is 50% drop of platelet in 24 hours. 
Thrombocytopenia is the principal and earliest coagulation abnormality that is 
present in all women with HELLP syndrome32,33. 
Laboratory abnormalities return to normal by fourth postpartum day, 
liver enzymes normalizes earlier than platelet count. Platelet count normalizes 
by 6-11 days33.   
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Liver dysfunction is reflected by variably elevated serum concentration 
of aspartate amino transaminase (AST), alanine aminotransaminase (ALT) and 
LDH. Indirect levels of bilirubin usually are minimally elevated except in 
patients with advanced severe disease. Raised total Lactate dehydrogenase 
isoenzyme is usually reflected in elevations of isoenzymes 5 (LDH 5 liver). 
LDH1 and LDH2 are released by ruptured RBC’s, but due to liver ischemia, 
the total LDH is elevated.   
A peripheral blood smear often will have evidence of schistocytes, burr 
cells and helmet cells which reflect damaged erythrocytes. Increases in Lactic 
dehydrogenase (LDH) levels and decreases in serum Haptaglobin levels are 
sensitive early markers of HELLP syndrome.  
A single A > G nucleotide substitution at position - 670 in the maternal 
but not neonatal TNFRSF6 gene coding for Fas is associated with a higher risk 
for HELLP syndrome (Sziller et al 2006)57. Significantly there will be a 
decreased expression of Pro apoptotic proteins BNip3 and Nix in the placenta 
of HELLP syndrome patients (Stepan H. et al 2005)58.  O Rh-negative had 
HELLP syndrome associated with an increase in risk by a factor of 3.1 (Sezik 
M & Coworkers 2002)59. 
Iioka (1996) reported that increased level of Human Hepatocyte growth 
factor may be useful in the early detection of HELLP syndrome. 
HELLP syndrome patients will have high plasma fibronectin and D-
dimer values, lower Antithrombin III and protein C activity (Paternoster et al. 
1995)31. 
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Significant over expression of Serum Amyloid A (SAA) in HELLP 
syndrome patients that could function as markers for the HELLP syndrome 
(Heitner JC et al 2006)56. 
HELLP syndrome should be taken into account in the case of 
unexplained elevated levels of MSHCG and MSAFP in the second trimester 
especially in the rare event of combined elevation of both markers (Morssink-
LP 1997)48. 
MANAGEMENT PROTOCOL FOR HELLP SYNDROME  
 Refer to Tertiary Medical Centre. 
 Admit in labor ward  
 Do laboratory investigation. 
 Prevent seizures with injection magnesium sulphate. 
 Control of blood pressure with anti-hypertensive. 
 Bed rest. 
 Fluid and electrolyte correction. 
 Hemotherapy with blood and blood products. 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
      
 
        
 
 
TREATMENT 
The successful management of pregnancy complicated by HELLP 
Syndrome requires 12 step approach for better maternal and perinatal outcome.  
1. ANTICIPATE AND CONFIRM THE DIAGNOSIS 
The patient with evidence of preeclampsia with imminent signs and 
symptoms must be seriously evaluated to rule out HELLP syndrome. Once the 
diagnosis of HELLP Syndrome is suspected, appropriate laboratory testing is 
indicated. In its early phases, HELLP syndrome can exhibit only modest 
increases in LDH, AST and ALT levels and mild thrombocytopenia (Class 3).  
Timely diagnosis and early recognition and the institution of the appropriate 
therapy facilitates the best possible outcome for a mother and her unborn child. 
Asses the maternal condition 
GA - < 24 weeks or > 34 weeks 
Maternal distress 
Eclampsia 
Abruptioplacenta 
Renal failure 
Pulmonary Edema 
DIC 
YES NO 
Deliver 
Deliver 
Complete steroid course for 24 Hrs 
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Risk Factors  
 
• BIO CHEMICAL  • Imminent signs and 
symptoms  
Platelets < 50,000/ µ L  Epigastric pain 
LDH > 1400 IU/L  Nausea 
AST > 150 IU/L  Vomiting 
ALT > 100 IU/L  Eclampsia 
Uric Acid > 7.8 mg/dl  Severe Hypertension 
Creatinine > 1.0 mg%  Placental Abruption 
 
2. ASSESS THE MATERNAL CONDITION 
Assess the maternal condition by clinically if there is maternal distress 
like Pulmonary Edema, DIC, MODS, etc., and if gestational age <24 weeks 
and more than 34 weeks and by all bio chemical investigations like CBC, 
urinalysis, serum creatinine, LDH, uric acid, indirect and total bilirubin levels, 
AST/ALT and coagulation profile. Serial assessments of the platelet count, 
LDH, and liver enzymes are reported usually every 12-24 hrs or more 
frequently if clinically indicated. 
3. ASSESS THE FETAL CONDITION:   DELIVER SOONER OR 
LATER 
HELLP syndrome is an atypical variant of severe preeclampsia and, as 
such, the only definitive treatment is delivery and removal of chorionic villi 
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and the cytotoxic factor(s) that it produces. The timing of delivery depends on 
a number of factors, including the severity of the maternal condition, fetal 
condition and placental reserve, and the gestational age.  
Fetal condition is assessed by fetal heart rate tracing, bio physical 
profile, or if GA is between 24 to 34 weeks there is a role for a course of steroids 
therapy for enhancing lung maturity. 
A National Institute of Health consensus panel in 1994 recommended 
that all patients with pregnancies between 24 and 34 weeks gestation at risk for 
preterm delivery be considered candidates for corticosteroid therapy to enhance 
fetal lung maturation/neonatal pulmonary function even if delivery might not 
be postponed the ideal 24-48 hour period66. RCOG committee on Obstetrical 
practice has now adopted these recommendations. 
4. CONTROL BLOOD PRESSURE (NICE Guide line 2010) 
Antihypertensives used in HELLP Syndrome for acute control of blood 
pressure  
 Labetalol  
o Starting doses 20mg IV followed by  
40mg and then 80mg at 10 – 15mins interval to a 
maximum doses of 220mg 
 Hydralazine  
o Starting doses 5mg IV followed by 
5 – 10mg IV every 20mins to a maximum doses 
20mg 
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 Nifedepine 
o Starting doses 10-20mg at 30mins interval maximum doses of 
50mg  
5. PREVENT SEIZURES WITH MAGNESIUM SULPHATE 
It is recommended that all HELLP syndrome patients receive 
intravenously infused MgSO4 given as a 4-6 gm intravenous bolus followed by 
a constant infusion rate of 2 mg/hr individualized to the patient. Continuation 
of the infusion 48 hrs or more into the puerperium occasionally is needed until 
evidence of recovery from HELLP syndrome is apparent. 
6. MANAGE WITH FLUID AND ELECTROLYTES 
Crystalloids and 5-25% of albumin  
7. EXERCISE JUDICIOUS HEMOTHERAPY 
 Packed cells  
 Fresh Frozen plasma  
 Platelet extract  
 Cryo precipitate  
8. MANAGE LABOUR AND DELIVERY 
Treatment of the patient with HELLP syndrome includes careful 
assessment of the maternal and fetal status, with delivery effected soon 
thereafter. 
This syndrome is not an indication for immediate delivery by caesarean 
section; vaginal delivery  allowed when the GA is more than 32 weeks or 
during active labour or rupture of membranes. Induction and augmentation of 
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labour with prostaglandins or oxytocin can be used. Cervical status and 
inducebility are important considerations when determining the likelihood of 
successful vaginal delivery in patient with HELLP syndrome54. 
Caesarean delivery is recommended when GA is < 30 weeks with 
unfavourable cervix, absence of   active labour, non-reassuring FHR, abnormal 
presentation, suspected abruption, severe oligohydraminos or IUGR are 
present.  
Management protocol for the HELLP Syndrome patient requiring 
caesarean section delivery 
 Surgery to be scheduled for 6 hours from the beginning of high dose of  
steroids to stabilize the disease process, improve laboratory parameters, reduced 
the need for blood product transfusions. (Tompkin O Bien)79 
1. General anesthesia 
2. Ten units of platelets prior to surgery if platelet counts < 50,000/cu mm. 
3. Vertical skin incision rather than a Pfannenstiel incision to minimise 
blood loss. 
Briggs et al concluded that for women with antepartum HELLP 
syndrome delivered by caesarean section, the frequency of wound 
complications is not influenced by type of skin incision or time of skin 
closure (Primary or delayed). 
4. Spontaneous placental delivery rather than manual extraction at 
caesarean is associated with a decreased blood loss, and less postpartum 
endometritis. 
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5. In situ rather than exteriorization for uterine repair is associated with 
less uterine and adnexal trauma. 
6. Bladder flap (vesicouterine peritoneum) should be left open. 
7. Subfascial drain (24 to 48 hours). 
8. Subcutaneous drain may be considered if the skin is approximated. 
9. Subcutaneous tissues should be approximated with sutures as evidenced 
by randomized trials and meta analysis for skin closure at caesarean 
delivery. 
10. Post operative transfusions as needed. 
11. Intensive monitoring for 48 hrs postpartum. 
ANAESTHESIA 
• Maternal analgesia can be provided by intermittent infusion of 
butorphanol or meperidine with promethazine. 
• Local infiltration 1% xylocaine for carefully controlled and skillfully 
executed non operative vaginal delivery. 
• Epidural anesthesia and pudendal block is contraindicated. 
• General anesthesia is the method of choice for caesarean delivery. 
• When coagulopathy is evident before surgery, intradural anaesthesia 
(low doses of Bupivacaine and fentanyl) is a safe option provided 
hemodynamic stability is assured (Blasi et al 1997)51. 
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9. OPTIMIZE PERINATAL CARE 
Pernatal mortality is 10-20% and it is due to prematurity, IUGR, 
respiratory distress, low birth weight. These babies are instituted NICU care for 
better perinatal out come.  
10. INTENSIVELY TREAT THE POSTPARTUM PATIENT 
• The diagnostic criteria for HELLP syndrome may develop antepartum 
or postpartum. Sebai and associates revealed that 70% had evidence of 
the syndrome antepartum and 30% developed the criteria postpartum. 
• In the postpartum group, the time of onset of the manifestations ranged 
from a few hours to 7 days, with the majority developing within 48 
hours after delivery. 
• HELLP syndrome may be diagnosed postpartum following 1 of 3 
clinical scenarios: 
1. Worsening of antepartum severe preeclampsia with delivery not yet 
altering the time course of the disease. 
2. New onset of severe preeclampsia postpartum. 
3. Rebound deterioration of a patient with antepartum HELLP syndrome 
after exposure to corticosteroid antepartum. 
• Patients in this group are at increased risk for the development of 
pulmonary edema and acute renal failure. 
• The goals of therapy postpartum differ compared with antepartum and 
are aimed solely at improving the maternal status. 
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• Management of seizure prophylaxis is similar to the antepartum patient 
with HELLP syndrome, including the need for MgSO4. 
• Hypertension control may be more aggressive, because there is no 
longer concern about compromising the uteroplacental circulation in the 
postpartum patient. 
• Martin and coworkers recommended the trial of plasma exchange with 
fresh frozen plasma be considered in HELLP syndrome that persists past 
72 hours from delivery and in which there is evidence of a life 
threatening microangiopathy33. 
11. REMAIN ALERT TO THE DEVELOPMENT OF MULTIPLE 
ORGAN SYSTEM FAILURE 
12. COUNSEL ABOUT FUTURE PREGNANCIES 
During the postpartum recovery period after a pregnancy with HELLP 
syndrome or at a later time remote from the index pregnancy, patients often ask 
for guidance about the recurrence risk for hypertension in general and HELLP 
syndrome specially in future pregnancies and 55% risk of recurrence if 
pervious delivery is less than 28 weeks.29  
Currently there is no preventive therapy for recurrent HELLP syndrome. 
Birth weight and gestational age are the most important factors in predicting 
the course of a subsequent pregnancy.   
There is higher incident of pre-eclampsia 20% in subsequent pregnancy 
in a patient who developed HELLP Syndrome (Facchinetti & Associates 2001). 
The overall incidence of recurrence is < 5%. The incidence of preterm delivery, 
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IUGR, abruption and IUD are higher in subsequent pregnancy. (Habli and 
associated 2009, Hnat and colleagues 2002).68 
SUBSEQUENT PREGNANCY COMPLICATIONS:  SIBAI ET AL (1995) 
1. Pre-eclampsia 19% 
2. Preterm delivery 21% 
3. IUGR 12% 
4. Abruptio placentae  2% 
5. Perinatal death  4% 
6. HELLP Syndrome 
3-
5% 
7. Chronic Hypertension  4% 
Recurrence Risk for HELLP Syndrome or Preeclampsia 
 HELLP Syndrome Pre eclampsia 
Sullivan et al 19 – 27% 23 - 43% 
Lie 1998 - 13% 
Van Pampus et al  2% 16% 
Chames et al  6% 55% 
Beinder et al 1996 reported that recurrence of HELLP Syndrome in four 
consecutive pregnancies in a patient.40 
Infants born to pre eclamptic mothers who develop HELLP Syndrome 
have an increased need for resuscitation at delivery and a higher incidence of 
postnatal cardio pulmonary instability (Raval et al 1997).47 
37 
Sibai et al (1995) reported that there is no evidence that oral 
contraceptives should be contraindicated after HELLP syndrome.35 
Steroids and the HELLP Syndrome  
"DEXAMETHASONE RESCUE" for HELLP SYNDROME 
ANTEPARTUM:  10 mg IV q 12 h 
1. Whenever < 100,000/ µL Platelets 
2. If Platelets 100,000 - 150,000/µL AND 
Eclampsia Severe Hypertension 
 Epigastric pain "Fulminant Disease" 
POSTPARTUM:  10 mg IV q 12 h x 2, then 5 mg IV q 12h x 2 individualised 
1. Whenever antepartum steroids given to avoid rebound 
2. Stop regimen after recovery evident (platelets > 100,000/ µL and LDH 
is trending downward and patients underlying preeclampsia / eclampsia 
is ameliorating 
The mechanism of action is unknown but appears to alter the final steps 
in endothelial cell disruption.75 Isler et al demonstrated intravenous dosing was 
superior to intramuscular dosing for several outcome variables including 
improving urine output and greater improvement in Laboratory values. 
High-Dose Glucocorticoid Therapy for severe HELLP Syndrome 
For most patients with HELLP syndrome, 10 mg intravenous dexamethasone 
every 6 hours for 2 doses followed by 6 mg intravenous dexamethosone 
every 6 hours for 2 additional doses. 
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For select patients at high risk, including those with profound 
thrombocytopenia (<20,000/ mm3) or with central nervous system dysfunction 
(i.e. blindness, paralysis), 20 mg intravenous dexamethasone every 6 hours for 
upto 4 doses. 
The duration of action of this medication is limited and patients may 
experience a worsening of their laboratory studies 48 to 72 hours after dosing 
with glucocorticoids. We term this as Rebound phenomenon. Steroid 
treatment, therefore, is not curative but may create a "Window of opportunity" 
for intervention before the maternal condition may again deteriorate. Because 
glucocorticoids do not appear to alter the underlying pathophysiology, delivery 
remains the only definitive therapy.75 
Intravenous immunoglobulins might be an attractive alternative 
treatment in persistently severe HELLP Syndrome (O-Pourrat et al 1992).20 
Another intervention to interrupt or ameliorate the clinical course of 
HELLP Syndrome includes the administration of nitric oxide. 
MATERNAL MORBIDITY AND MORTALITY 
 Maternal morbidity and mortality is high in a patient with HELLP 
Syndrome particularly with complete HELLP Syndrome. Class-I and II have 
more complication than class-III.  
In a review of 34 HELLP syndrome related mortalities, the authors 
discovered that the presenting symptom in 90% of patients who died was nausea-
vomiting and right upper quadrant pain, the mean gestational age was 31 weeks, 
death occurred by a variety of pathologic processes, including sepsis, shock 
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hemorrhage, intra cerebral bleeding and cardiopulmonary failure. Approximately 
one in six (16%) maternal deaths was attributed to hepatic complications. A large 
percentage of maternal deaths attributed to central nervous system catastrophic 
events. The most important biochemical marker for maternal mortality is bilirubin 
levels. Maternal mortality was statistically higher in cases with jaundice (Demir 
SC et al 2006).60 
Associated DIC is an important aggravating factor, often leading to 
deterioration of the maternal status, Van Dam et al (1989) suggested a semi 
quantitative DIC scoring system introduced by Hellgren et al (1984).65 This 
DIC score is based on platelet count less than 100 x 10 9/7, Prothrombin time 
< 70%, antithrombin III activity < 80%, fibrin degradation products over 40 
mg/L and fibrinogen < 300 mg/dl.  Three or more pathologic tests were 
considered as manifest DIC and two as suspected DIC. DIC score may be a 
sensitive index for detecting deteriorating maternal condition in HELLP 
syndrome and its use could reduce maternal morbidity and mortality from DIC. 
From Sibai et al (2003)53 
1. Disseminated intravascular coagulopathy 21% 
2. Abruptio placentae 16% 
3. Acute renal failure 8% 
4. Severe ascitis 8% 
5. Pulmonary edema 6% 
6. Pleural effusions 6% 
7. Cerebral edema 1% 
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8. Retinal detachment 1% 
9. Laryngeal edema 1% 
10. Subcapsular liver hematoma 1% 
11. Acute respiratory distress syndrome 1% 
A rare but interesting complication of HELLP Syndrome is transient 
Diabetes Insipidus (Mabie & Sibai 16 1990).11 It is characterised by a resistance 
to arginine vasopressin mediated by excessive vasopressinase. It is postulated 
that elevated circulating vasopressinase may result from impaired hepatic 
metabolism of the enzyme. The best prophylaxis against development of life 
threatening complications is early diagnosis and termination of pregnancy after 
stabilisation of the maternal condition, consisting of magnesium sulphate 
infusion, antihypertensive treatment with dihydralazine or calcium antagonists, 
steroids etc. As prophylaxis against postpartal worsening of HELLP syndrome, 
curettage of the uterus and continuation of the treatment with antihypertensives 
and dexamethasone have been recommended. 
Maternal mortality is due to  
 DIC  
 MODS 
 Pulmonary edema  
 Intra cerebral haemorrage  
 Post cesarean shock 
 Hepatic rupture. 
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PERINATAL MORBIDITY AND MORTALITY  
Perinatal morbidity and mortality in HELLP Syndrome is 10-20%. 
Mortality increase with early gestational age. The incidence of preterm delivery 
is 70%. Mortality is high due to preterm, low birth weight, IUGR, abruption. 
Infant will have high rate of bronchopulmonary dysplasia, intra cerebral 
haemorrhage, necrotizing enterocolitis.  
Perinatal mortality 33% (Sibai et al 1986, Eeltink et al 1993)10 reported 
• Small for gestational age 44% 
• Perinatal asphyxia 21.6% 
• Neonatal respiratory distress 43.2% 
• Hyperbilirubinemia 44.7% 
• Persistent ductus arteriosus 16.2% 
• Thrombocytopenia 34% 
• Hypoglycemia 16.2% 
CAUSES FOR PERINATAL DEATH 
1. Abruptio placentae 
2. Intrauterine asphyxia 
3. Prematurity 
The combination of HELLP syndrome and eclampsia results in a greater 
number of preterm infants with lower birth weights and higher mortalities than 
eclampsia alone.  
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MATERIALS AND METHODS 
METHOD OF COLLECTION OF DATA 
Analysis of 100 cases of severe preeclampsia / eclampsia with HELLP 
syndrome and without HELLP syndorme during the year 2015 in Tirunelveli 
Medical College Hospital, Tirunelveli to determine the occurrence and course 
of HELLP Syndrome in order to make a timely intervention and to render 
optimal patient treatment, a better maternal and perinatal outcome. 
The patients were divided into 2 groups 
 Severe Preeclampsia / Eclampsia with HELLP syndrome 
(HELLP Group) 
 Severe Preeclampsia / Eclampsia without HELLP 
syndrome(NON-HELLP Group) 
History regarding age, parity, gestational age, menstrual history and 
pervious illness were noted.  A thorough general and other systemic 
examination were done with obstetric examination. 
The observations done were 
1. Weight of the patient 
2. Albuminuria 
3. Blood Pressure 
4. Haemoglobin 
5. Platelet count 
6. Peripheral smear 
7. Serum Bilirubin estimation 
43 
8. SGOT estimation 
9. SGPT estimation 
10. BT 
11. CT 
12. Serum fibrinogen 
13. Sr. LDH estimation 
14. Blood urea and serum uric acid estimation 
15. Serum Creatinine estimation 
16. Fundus examination 
Both groups were in admitted in labour ward kept under careful 
monitoring investigations like CBC, RFT, LFT, BT, CT, PT, aPTT, Fibrinogen 
were sent, and the intervention: 
General Nursing Care, Electrolyte balance, monitoring urine output, 
Medical Management. 
1. Antithypertensive drugs 
2. Prophylactic Mgso4 for server preeclampsia  
Obstetric Management  
 Termination of pregnancy – based on Bishop score 
 If Bishop Score is favourable, labour will be accelerated with oxytocin 
drip and ARM. 
 If Bishop Score is unfavourable induction of labour with 
prostaglandins will be done. 
 Caesarian section will be done for obstetric indications. 
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The women and newborn will be monitored for 1 week in the post 
partum period. 
Outcome will be measured in terms of age of the mother, parity, 
socioeconomic status, antenatal care status, duration of gestation BP and 
degree of proteinuria, delivery interval, mode of delivery, perintal outcome and 
maternal outcome. Data obtained will be tabulated and analysed 
systematically.  
According to NICE guidelines severe preeclampsia is managed 
conservatively until 34 weeks and delivery is recommended after a course of 
Corticosteroids after 34 weeks. 
Delivery is recommended in a case of severe preeclampsia before 34 
weeks after completion of steroids if severe hypertension is develops refractory 
to treatment and for maternal and fetal indication.  
Source of data 
Present clinical study will be carried on 100 cases of severe 
preeclampsia and eclampsia above 28 weeks of gestational age with HELLP 
syndrome admitted in Medical college Hospital, Tirunelveli for a period of 6 
month from Feb 2015 to July 2015. These patient will be followed up 
prospectively till delivery. 
Sample size: 100 cases  
INCLUSION CRITERIA 
 All pregnant women above 28 weeks of gestational age with severe 
preeclampsia / eclamosia with one or more of the following: 
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 Hemolysis detected by either Peripheral smear or Elevated Indirect 
bilirubin or Elevated LDH levels. 
 Elevated liver enzymes. 
 Decreased Platelet count < 100,000/cumm. 
Exclusion criteria  
1. Known case of Hepatic disease. 
2. Known case of Hemolytic Anaemias. 
3. Known case of Platelet disorders. 
4. Chronic hypertension in Pregnancy. 
5. Chronic renal Diseases.  
6. Placenta praevia. 
7. Acute Fatty liver of Pregnancy. 
Statistical analysis required  
 This prospective study requires Chi Square test for analysis. 
PERIPHERAL SMEAR 
Spreading the Film 
Properly spread film is essential to accurate work. 
1. The slides and cover glasses must be perfectly clean 
2. Drop of blood must not be too large 
3. The work must be done quickly 
The blood is obtained from the finger tip. Take a small drop of blood on 
a clear slide about 3/4 inch from the end taking care that the slide does not 
touch the skin. Place the end of a second slide against the surface of the first an 
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angle of 30-40o and draw it against the drop of blood, push the spreader slide 
back along the other. The blood will follow and then smears should be made. 
The film may be allowed to dry in the air. Leishman's stain is added, and after 
2 mts double the quantity of distilled water are added to the stain and waited 
for 7-10 mts. Then the stain is washed in the tap water and slide dried in air and 
viewed under oil immersion. 
The mature red corpuscle appears greenish yellow in unstained 
preparations and is roughly circular in shape and seen on edge as biconcave 
disc. Cells with reduced concentration of heamoglobin are called hypochromic 
which may be so extensive that only a narrow rim of haemoglobin is left around 
the periphery. There cells are called pessary cells. 
Spherocyte are small darkly staining cells. Burr cells are mature red cells 
which possess one or more spiky projecting on their periphery seen in 
microangiopathic haemolytic anaemia. 
 SERUM BILIRUBIN ESTIMATION 
Methods of detecting and estimating Bilirubin in serum are based on the 
formation of the purple compound when bilirubin reacts with the diazo reagent 
introduced by vanden Berg. 
Reagents 
1. Absolute method 
2. Diazo reagent prepared freshly by adding 0.3 ml of solution B to 10 ml 
of solution A. 
 
47 
a. Solution A 
Dissolve 1 gm of sulphuric acid in 15 ml concentrated HC1 and make it 
to i liter with distilled water. 
b. Solution B 
- 0.5% sodium nitrite in water prepared at frequent intervals. 
- Prepare a solution containing 10 mgm/100ml of chloroform. It 
may be necessary to reflex the mixture gently to dissolve the 
bilirubin. 
Technique 
Wash 0.2 ml of serum into 5.4 ml of 0.9% saline. For values above 15 
mgms/0.1 ml serum in 5.5 ml water may be taken serum 0.2, 5.6 ml divided 
into 4 parts of 1.4 ml each. 
 Total Bilirubin Direct Bilirubin 
Test Control Test Control 
Dilute 
Screen 
1.4 ml 1.4 ml 1.4 ml 1.4 ml 
UDBA - 0.35 ml - 0.35 ml 
Diazo 
reagent 
0.35 - 0.35 - 
Water - - 1.75 1.75 
Methanol 1.75 1.75 - - 
Let it stand for 10 mts read against water blank at 530mμ photoelectric 
colorimeter. 
48 
Standardization 
Mg/bilirubin per 100 ml 0-10-20-30-40 
MI Standard solution 0.1 0.2 0.3 0.4 - 
MI Chloroform 2.8 2.7 2.6 2.5 2.4 
Diazo reagent 0.7 0.7 0.7 0.7 0.7 
Methanol 3.5 3.5 3.5 3.5 3.5 
Bilirubin Normal Value Total <1mg% 
LDH ESTIMATION 
Sample 
Although serum is preferred, plasma can be used only if heparin or 
EDTA is used as an anticoagulant.  
Serum or plasma should be separated from the blood sample as early as 
possible. 
Serum or plasma can be used stored at 2-8oC for one week. 
Reagents: The Ames Autopak LDH reagent kit 
1. NADH 
1A. Buffer 
2. Pyruvate 
Preparation of working solutions 
Allow the reagents to attain the room temperature. The Ames Autopak 
LDH reagent kit contains three bottles/vials each of reagent 1 & 1A and one 
bottle of reagent 2. 
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Solution (1): Transfer a small amount of the contents of one bottle (1A) into one 
bottle  
(1). Mix gently to dissolve and transfer the solution back to bottle 
(1A). Rinse bottle (1) with solution in bottle (1A). 
Reagent (2): Ready for use 
Preparation of Daily working solutions 
Allow the solution (1) and reagent (2) to attain the room temperature. 
The daily working solution should be prepared fresh according to the 
need. Mix 10 volumes of solution (1) with 1 volume of reagent (2) to obtain 
daily working solution. 
Storage and stability of the Reagents 
Expiry date of reagents stored at 2-8oC is indicated on the box label. 
Solution (1) is stable for six weeks at 2-8oC Reagent (2) is stable at 2-8oC until 
the end of expiry date on the table. 
Procedure 
The samples and the daily working solution should be brought to room 
temperature prior to use. The general system parameters are 
Reaction Type  : Kinetic 
Wavelength  : 340mm 
Flow cell 
temperature 
 
: 37oC 
Delay time  : 60 Sec 
No. of Readings  : 4 
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Interval  :           30 Sec 
Sample Volume  : 30 μl 
Reagent Volume  : 1.0 ml 
Pathlength  : 1 cm 
Factor  : 5520 
Zero setting with  : Distilled water 
Procedure limitations 
Plasma can be used only if heparin or EDTA is used as an anticoagulant 
Citrate and oxalate interfere with the test and hence should not be used. 
Do not use haemolysed samples as haemolysis may give falsely elevated 
results. 
The method is linear upto 1000 IU/L. For higher values, dilute the 
sample suitably with 0.9% saline and repeat the assay. Apply proper dilution 
factor to calculate the final results. 
Normal Values 
Upto 600 IU/L (37oC) 
SGOT ESTIMATION 
Sample Collection, Storage and Stability 
Although serum is preferred, plasma can be used. Anticoagulants such 
as heparin and EDTA can be used. Blood samples may be collected any time, 
although morning samples are preferred. 
Samples with any visible hemolysis are not acceptable. Samples are stable for a  
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week at 2-80 C and for one month at 10oC samples should be brought to room 
temperature prior to use. 
Reagents 
1. Aspartate/Buffer 
1A. NADH/MDH/LDH 
2. Alpha-Ketoglutarate 
Preparation of working solutions 
Allow the reagents to attain the room temperature. 
Solution (1): Quantitatively transfer the contents of Via 1A into bottle 1. Mix 
until completely dissolved. 
Solution (2):Dissolve the contents of bottle 2 with 14 ml of distilled water. 
Preparation of daily working solutions 
Allow the solutions (1) and (2) to attain the room temperature. 
The daily working solution should be prepared freshly according to the 
need in the proportions given below: Solution (1): 3.0 ml 
Solution (2): 0.3 ml 
Mix thoroughly, use within 8 hours of preparation - store at 2-80C. 
Storage and stability of Reagents 
Expiry date of reagents stored at 2-80C are 
Solution (1): for 3 months 
Solution (2): for 4 months 
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Procedure 
The samples and the daily working solution should be at the room 
temperature prior to use. The following general system parameter are used. 
Reaction Type : Kinetic 
Wavelength : 340 mm 
Flowcell Temp : 370C 
Delay Time : 60 Sec 
No. of Readings : 4 
Interval  :           30 Sec 
Sample Volume : 100 ml 
Reagent Volume : 1.0 ml 
Pathlength : 1 cm 
Factor : 1749 
Zero setting with : Distilled water 
Procedure limitations 
• Haemolysis of sample can produce a significant positive error as red 
cells contain large amounts of GOT (AST). 
• Samples with very high GOT activity cause an excessive consumption 
of NADH, resulting in a very low initial absorbance. When this occurs, 
the assay should be repeated with a diluted sample. 
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• Linearity of the method is upto 400 IU/L for higher values, dilute the 
sample suitably with 0.9% saline and repeat the assay. Apply proper 
dilution factor to calculate the final results. 
Normal Values 
Upto 40 IU/L (37oC) 
SGPT ESTIMATION 
Sample 
Although serum is preferred, plasma can also be used with 
anticoagulants such as heparin or EDTA. 
Serum or plasma GPT determination should be carried out on the same 
day as far as possible. 
Samples are stable for about 3 days when stored tightly capped at 2-80C 
or for two weeks at – 10oC. 
Avoid using haemolysed or grossly contaminated samples. The samples 
should be brought to room temperature prior to use. 
Reagents 
1. Alanine / Buffer  1A. NADH/LDH 
2. Alpha - Ketoglutarate 
Preparation of working solutions, storage and stability of reagents, 
procedure & procedure limitation. 
Same as that for SGOT. 
Normal values 
Upto 40 IU/L (37oC) 
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METHOD OF COUNTING PLATELETS 
Rapid work is necessary in order to prevent clumping of the 
thrombocytes. Rees & Eker diluting fluid drawn upto 1 mark in the red pipette. 
Blood from a freely bleeding puncture is drawn exactly to the 0.5 mark and 
finally the diluting fluid is quickly drawn to the 101 mark. This gives a blood 
dilution of 1:200. The blood and diluting fluids are immediately mixed by 
shaking for about 2 mts. The counting chamber is filled at once and 10 mts are 
allowed for the corpuscles to settle before counting is begun. The count is made 
with high power dry objective and with the 10x ocular in the manner described 
for counting erythrocytes. A central count of the thrombocytes should always 
be made at the same time with the same diluting fluid and exactly the same 
technique. Platelet count were also obtained from peripheral smear. 
Platelets are disc shaped being 2-4 μm in diameter and 0.5 to 1mm in 
thickness. They have no nucleus and their cytoplasm has many azurophil 
granules which in blood films tend to be concentrated in the middle. The 
precursor for the platelet is megakaryocytes. The platelets are formed by 
fragmentation and detachment of delicate processes from cytoplasm of 
megakaryocyte. The normal platelet count varies from 150000 to 400000/mm3. 
A count below 100000/mm3 can be taken as thrombocytopenia. 
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STATISTICAL ANALYSIS: 
The group with HELLP syndrome and the group without HELLP syndrome 
have been described and interpreted according to their demographic, social, 
physiological biochemical and obstetric characteristics. The maternal outcome of 
and perinatal outcome were analyzed and interpreted as follows. In the above 
description and analysis, the measurable variables were compared between the two 
by mean and standard deviations. The student t test was applied to infer the 
significance of difference between the means. The categorical variables were 
compared between them by Chi-square test (χ2). The statistical analysis and 
interpretations have been performed by the statistical software IBM SPSS-
sdtatistics-20. The P-value less than 0.05 (P<0.05) was treated as statistically 
significant in two tail test. 
RESULTS:  
 The group with HELLP syndrome and group without HELLP syndrome 
were described and compared between the demographic, economic, physiological, 
biochemical and obstetrics characteristics. Among the selected 100 mothers, 43 
mothers were having HELLP syndrome and the remaining 57 did not have the 
HELLP syndrome.   
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DEMOGRAPHIC CHARACTERISTICS 
The study subjects were described according to their age and compared between 
them. 
Table: 1. Percentage distribution of study subjects according to their age: 
Age group HELLP 
syndrome 
No HELLP 
syndrome 
Total 
No % No % No % 
15-19 3 7.0 5 8.8 8 8.0 
20-24 19 44.2 21 36.8 40 40.0 
25-29 12 27.9 22 38.6 34 34.0 
30-34 9 20.9 9 15.8 18 18.0 
Total 43 100.0 57 100.0 43 100.0 
Mean ±SD 25.2 ±4.3 25.0±4.1 25.1±4.2 
‘t’ t=0.260 Age range = 18-34 
Significance P>0.05 
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44.2% of HELLP group belong to the age group of 20-24 years, and 38.6% 
of Non-HELLP group belong to the age group of 25-29 years. Hence the 
difference between the two group were not statistically significant (P>0.05). 
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SOCIO ECONOMIC CHARACTERISTICS 
 The socio economic characteristics of the HELLP syndrome subjects were 
studied to identify the association between socioeconomic status and HELLP 
syndrome. 
Table: 2. Association between HELLP syndrome and socio economic 
status(SES): 
SES HELLP Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
2.043 2 P>0.05 
III 4 9.3 2 3.5 6 6.0 
IV 18 41.9 31 54.4 49 49.0 
V 21 48.8 24 42.1 45 45.0 
Total 43 100.0 57 100.0 100 100.0 
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48.8% of HELLP group belongs to 5th socio economic status and 54.4% of 
Non-HELLP group belong to 4th socio economic status. But the SES of study does 
not show any significant association between both groups (P>0.05).  
PHYSIOLOGICAL CHARACTERISTICS 
 The study subjects namely HELLP syndrome cases were studied according 
to their physiological characteristics namely weights, Systolic BP and Diastolic 
BP. The same was compared with non HELLP syndrome cases. 
Table: 3. Comparison of Weight, SBP and DBP between HELLP and non 
HELLP: 
Variable HELLP, 
n=43 
Non 
HELLP, 
n=57 
Difference 
b/w 
means 
‘t’ df Significance 
Mean SD Mean SD 
Weight 56.7 6.5 56.6 5.0 0.1 0.027 98 P>0.05 
SBP 162.9 19.8 160.0 14.9 2.9 0.844 98 P>0.05 
DBP 112.4 11.9 112.3 10.3 0.1 0.020 98 P>0.05 
  
 The mean SBP of HELLP and non HELLP group was 162.9±19.8 and 
160.0±14.9 mm/hg respectively. The mean DBP of HELLP and non HELLP group 
was 112.4±11.9 and 112.3±10.3 mm/hg respectively. The difference of means 
between both groups was not statistically significant (P>0.05).  
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BIOCHEMICAL CHARACTERISTICS 
 The biochemical variables like blood urea, serum creatinine, Hemoglobin, 
Serum uric acid, Serum bilirubin-Total, Serum bilirubin-Direct, and Serum 
bilirubin-Indirect have been studied and compared between the HELLP and non 
HELLP mothers. 
Table: 4. Comparison of biochemical variables between HELLP and non 
HELLP: 
Variable HELLP, 
n=43 
Non 
HELLP, 
n=57 
Difference 
b/w 
means 
‘t’ df Significance 
Mean SD Mean SD 
BU 25.3 10.6 24.2 8.4 1.1 0.578 98 P>0.05 
SC 1.2 1.1 1.1 1.7 0.1 0.246 98 P>0.05 
UA 7.2 1.6 6.7 1.8 0.5 1.479 98 P>0.05 
 
The mean blood urea (BU) of HELLP and Non HELLP syndrome mothers 
were 25.3±10.6 and 24.2±8.4 respectively. The difference between them was not 
statistically significant (P>0.05). The mean serum creatinine of both groups was 
1.2±1.1 and 1.1±1.7 respectively. The difference of means was not statistically 
significant (P>0.05). The mean uric acid (UA) of HELLP group was 7.2±1.6 and 
the same of non HELLP group was 6.7±1.8. The difference was also not 
statistically significant (P>0.05). 
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Table: 4.1. Comparison of biochemical variables between HELLP and non 
HELLP 
Variable HELLP, 
n=43 
Non 
HELLP, 
n=57 
Difference 
b/w 
means 
‘t’ df `Significance 
 Mean SD Mean SD 
HB 7.8 2.5 10.8 8.4 3.0 2.223 98 P<0.05 
 
The mean Hemoglobin level of HELLP syndrome group was 7.8±2.5 and 
non HELLP group was 10.8±8.4. The mean difference between the two groups 
was statistically significant (P<0.05).  It shows there is drop in Hemoglobin level 
in HELLP than Non-HELLP group. 
Table: 4.2. Comparison of biochemical variables between HELLP and non 
HELLP 
Variable HELLP, 
n=43 
Non 
HELLP, 
n=57 
Difference 
b/w 
means 
‘t’ df `Significance 
 Mean SD Mean SD 
S B-T 1.9 1.5 0.8 2.3 1.1 5.156 98 P<0.001 
S B-D 0.8 0.6 0.5 0.2 0.3 3.648 98 P<0.001 
S B-I 1.1 1.0 0.3 0.1 0.8 5.475 98 P<0.001 
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The mean serum biluribin Total, Direct and Indirect of HELLP group was 
1.9±1.5, 0.8±0.6 and 1.1±1.0 respectively. Similarly, the mean serum biluribin 
Total, Direct and Indirect of non HELLP group was 0.8±2.3, 0.5±0.2 and 0.3±0.1 
respectively. The differences between the groups were statistically very highly 
significant (P<0.001). The serum indirect biluribin was more among HELLP 
syndrome. 
Table: 5. Association between HELLP syndrome and Urine Albumin: 
UA HELLP Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
5.180 3 P>0.05 
+ 2 4.7 4 7.0 6 6.0 
++ 13 30.2 22 38.6 35 35.0 
+++ 21 48.8 29 50.9 50 50.0 
++++ 7 16.3 2 3.5 9 9.0 
Total 43 100.0 57 100.0 100 100.0 
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48.8% among the HELLP group has more than 3+ proteinuria and 50.9% 
among the Non HELLP has proteinuria.  The above table show the there is 
significant proteinuria in both HELLP and Non-HELLP group and they are not 
statically significant p>0.05.  
OBSTETRIC CHARACTERS 
 The HELLP mothers were described according to their obstetric characters 
like gravida, gestational age and Fundus, 
Table: 6. Association between HELLP syndrome and gravida: 
Gravida HELLP Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
5.054 1 P<0.05 
Primi 19 44.2 38 66.7 57 57.0 
Multi 24 55.8 19 33.3 43 43.0 
Total 43 100.0 57 100.0 100 100.0 
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55.8% of pregnancy in HELLP group were multi gravida and 57% of 
pregnancy in Non-HELLP group were primi gravida. According to the above table 
HELLP syndrome shows higher incidence in multipara.  
Table: 7. Comparison of Gestational age of HELLP with non HELLP. 
HELLP Non-HELLP Difference 
b/w means 
‘t’ df Significance 
Mean SD Mean SD 
33.2 3.5 34.8 3.1 1.6 2.424 98 P>0.05 
 
The mean gestational age of HELLP group was 33.2±3.5 weeks and the 
same of the non HELLP group was 34.8±3.1 weeks. The difference between them 
was not statistically significant (P>0.05). According to the above table HELLP 
syndrome is more common around 33 -34weeks of gestation.   
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Table: 8. Comparison of Fundus between HELLP and Non HELLP: 
Fundus HELLP Non-
HELLP 
Total χ2 df Significance 
No % No % No % 0.194 2 P>0.05 
Grade-I 5 11.6 8 14.0 13 13.0 
Grade-
II 
2 4.7 2 3.5 4 4.0 
Normal 36 83.7 47 82.5 83 83.0 
Total 43 100.0 57 100.0 100 100.0 
 
 
In both groups, the fundus was normal as 83.7% and 82.5% respectively. 
There was no significant association between them (P>0.05). 16.3% cases had 
fundus changes in HELLP syndrome. 
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HELLP criterion characteristics: 
 The HELLP criterion measurements namely SGOT, SGPT, LDH and 
platelet have been compared between the HELLP and non HELLP mothers. 
Table: 9. Comparison of SGOT, SGPT, LDH, Platelet between HELLP and non 
HELLP: 
Variab
le 
HELLP, n=43 
Non 
HELLP, 
n=57 
Differen
ce b/w 
means 
‘t’ 
d
f 
Significan
ce 
Mean SD Mean SD 
SGOT 111.6 59.2 35.9 24.0 75.7 8.717 
9
8 
P<0.001 
SGPT 122.6 101.0 35.2 25.4 87.4 6.282 
9
8 
P<0.001 
LDH 1452.6 1136.5 246.9 
171.
9 
1205.7 7.902 
9
8 
P<0.001 
Platele
t 
69113.
5 
26919.
7 
19431
5 
6099
9 
125202.3 
12.55
7 
9
8 
P<0.001 
 
The mean SGOT, SGPT, LDH and Platelet of HELLP group were 111.6 ± 
59.2, 122.6±101.0, 1452.6 ±1136.5 and 69113.5±26919.7 respectively. The same 
of the non HELLP group were 35.9±24.0, 35.2±25.4, 246.9±171.9and 
194315±60999 respectively. The differences between the measures of the groups 
were statistically very highly significant (P<0.001). Isolated elevation of liver 
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enzymes are found in Non-HELLP group but there is significant elevation of liver 
enzymes in HELLP syndrome. 
Table: 9.1. Platelet 
Platelet HELLP syndrome 
No. of Cases Percentage 
Class-I < 50000 13 30.2% 
Class-II  50000 – 1 lakh 24 55.8% 
Class-III 1 lakh -  1.5 
lakh 
6 14% 
  
 According to the above table 30.2% of HELLP syndrome belonged to class-
I, 55.8% belong to class-II, and 14% belong to class-III.   
Table: 10.Association of Pre-Eclampsia or Eclampsia associated with HELLP 
mothers: 
TYPE 
HELLP 
Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
4.610 1 P<0.05 
Pre 
Eclampsia 
39 90.7 42 73.7 81 81.0 
Eclampsia 4 9.3 15 26.3 19 19.0 
Total 43 100.0 57 100.0 100 100.0 
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From the above table -9, 90.7% of Pre-Eclampsia was associated with HELLP 
syndrome. The association between them was statistically significant (P<0.05). 
HELLP syndrome is more come in severe preeclamptic patients. 
Table: 11. Symptoms classified between the HELLP and non HELLP. 
 
Symptoms 
HELLP Non HELLP Total 
No % No % No % 
Nil 8 18.6 22 38.6 30 30.0 
↓UO 7 16.3 3 5.3 10 10.0 
B/H 1 2.3 0 0.0 1 1.0 
C 7 16.2 14 24.6 21 21.0 
H 17 39.6 13 22.9 30 30.0 
V 3 7 5 8.8 8 8.0 
Total 43 100.0 57 100.0 100 100.0 
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 Table: 12. Comparison of incidence of symptoms between HELLP & 
non HELLP: 
TYPE 
HELLP 
Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
4.665 1 P<0.05 
Symptoms 35 81.4 35 61.4 70 70.0 
No 
symptoms 
8 18.6 22 38.6 30 30.0 
Total 43 100.0 57 100.0 100 100.0 
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81.4% of HELLP group patient present with symptoms and 61.4% of Non-
HELLP group patient present with symptoms. The association of symptoms with 
HELLP is statistically significant p<0.05. 
Table: 13. Peripheral Smear associated with HELLP: 
Peripheral 
Smear 
HELLP 
Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
71.023 1 P<0.001 
Burrcell 11 26.6 2 3.5 13 13.0 
Fragment 9 20.9 0 0.0 9 9.0 
NHBP 6 14.0 55 96.5 61 61.0 
Schistoc 17 39.5 0 0.0 17 17.0 
Total 43 100.0 57 100.0 100 100.0 
 
Symptoms No symptoms
81.40%
18.60%
61.40%
38.60%
Comparison of incidence of symptoms between HELLP & 
non HELLP
HELLP Non-HELLP
71 
 
 
86% of HELLP group shows micro angiopathic haemolysis and only 3.5% 
of Non-HELLP group shows haemolysis. Hence the Peripheral smear results such 
as Burrcell, Fragmented cells and Schistocytes were very strongly associated with 
HELLP groups (P<0.001). 
MATERNAL OUTCOME 
 The maternal outcome of HELLP group was studied in respect of their 
Term of delivery, mode of delivery, blood transfusion, complications and 
condition of mothers.  
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Table: 14. Association between preterm / term delivery with HELLP. 
Term 
HELLP 
Non-
HELLP 
Total 
χ2 df Significance 
No % No % No % 
Pre 
term 
36 83.7 37 64.9 73 73.0 
4.399 1 P<0.05 
Term 7 16.3 20 35.1 27 27.0 
Total 43 100.0 57 100.0 100 100.0 
 
 
83.7% of HELLP group had preterm delivery and 64.9% of Non-HELLP 
group had preterm delivery. The HELLP group were statistically associated with 
pre term delivery (P<0.05). 
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Table: 15. Association between mode of delivery with HELLP. 
Mode 
of 
delivery 
HELLP Non-
HELLP 
Total χ2 df Significance 
No % No % No % 
Labour 
Natural 
24 55.8 25 43.9 49 49.0 
3.049 3 P>0.05 Forceps 1 2.3 2 3.5 3 3.0 
LSCS 18 41.9 30 52.6 48 48.2 
Total 43 100.0 57 100.0 100 100.0 
 
 
Among the HELLP group 55.8% delivered by LN, 2.3% by forceps, 41.9% 
by LSCS. Among the Non-HELLP group 43.9% delivered by LN, 3.5% by 
forceps, 52.6% by LSCS. There was no significant association between both 
groups. P>0.05. 
Natural Forceps LSCS
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Table: 16. Association between blood transfusion with HELLP. 
Blood 
transfusio
n 
HELLP Non-
HELLP 
Total χ2 d
f 
Significanc
e 
N
o 
% N
o 
% No % 
Nil 5 11.6 45 78.9 50 50.0 49.68
4 
2 P<0.001 
PCT 12 27.9 9 15.8 21 21.0 
PCT/pdt 26 60.5 3 5.3 29 29.0 
Total 43 100.
0 
57 100.
0 
10
0 
100.
0 
 
 
In the above table 84.4% of HELLP group required blood and blood 
product transfusion and only 21.1% of Non-HELLP group required blood 
transfusion. Hence there was need for blood transfusion in HELLP group which 
highly significant (P<0.001). 
Nil PCT PCT/pdt
11.60%
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5.30%
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Table: 17. Type of Complications with HELLP and Non HELLP. 
Complications HELLP Non-HELLP Total 
No % No % No % 
Nil 22 51.2 45 78.9 67 67.0 
Abrubtio 9 20.9 6 10.5 15 15.0 
ARF 7 16.2 2 3.5 9 9.0 
Cerebral 1 2.3 1 1.8 2 2.0 
CVT 1 2.3 1 1.8 2 2.0 
DIC/Pulmonary 
Edema 
1 2.3 0 0.0 1 1.0 
Plueral/ 
effusion 
1 2.3 1 1.8 2 2.0 
PRES 0 0.0 1 1.8 1 1.0 
SEPSIS 1 2.3 0 0.0 1 1.0 
Total 43 100.0 57 100.0 100 100.0 
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Table:18. Association between complications with HELLP. 
Complication
s 
HELLP 
Non-
HELLP 
Total 
χ2 
d
f 
Significanc
e N
o 
% 
N
o 
% No % 
Nil 22 51.2 45 78.9 67 67.0 
8.55
8 
1 P>0.01 
Yes 21 48.8 12 21.1 33 33.0 
Total 43 
100.
0 
57 
100.
0 
10
0 
100.
0 
 
 
From above table 48.8% cases among the HELLP group developed 
complication and 21.1% cases among the Non-HELLP group developed 
complication. So the complication was strongly associated with HELLP syndrome 
group. 
Nil Yes
51.20% 48.80%
78.90%
21.10%
Association between complications with HELLP
HELLP Non-HELLP
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Table:19. The condition of patient associated with HELLP syndrome: 
Condition 
HELLP 
Non-
HELLP 
Total 
χ2 
d
f 
Significanc
e N
o 
% 
N
o 
% No % 
Expired 5 11.6 0 0.0 5 5.0 
9.97
7 
2 P<0.01 
Normal 
Maternal 
Outcome 
36 83.7 57 
100.
0 
93 93.0 
Recovered 
after 
hemodialysi
s 
2 4.7 0 0.0 2 2.0 
Total 43 
100.
0 
57 
100.
0 
10
0 
100.
0 
 
83.7% of case among HELLP group had normal maternal outcome and 
100% of case among Non-HELLP group had normal maternal outcome. There 
was 11.6% mortality among the HELLP group hence mortality is strongly 
associated with HELLP syndrome.  
Expired Normal Maternal
Outcome
Recovered after
hemodialysis
11.60%
83.70%
4.70%0%
100%
0%
The condition of patient associated with HELLP 
syndrome
HELLP Non-HELLP
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Perinatal outcome: 
 The perinatal outcome was studied for Foetus. Among the HELLP group 
one patient had twins and all 42 mothers had singleton pregnancy. In HELLP 
group perinatal outcome was 44. 
Table: 20.Comparison of Perinatal outcome between HELLP and non HELLP    
Outcome 
HELLP 
Non-
HELLP 
Total 
χ2 df Significance 
No % No % No % 
APO 24 54.5 14 24.6 38 37.6 
9.513 1 P<0.001 NPO 20 45.5 43 75.4 63 62.4 
Total 44 100.0 57 100.0 101 100.0 
 
54.5% of babies among HELLP group had an abnormal perinatal outcome 
and 24.6% of babies among Non-HELLP group. Hence HELLP group is strongly 
associated with abnormal perinatal outcome. The association is statistically very 
highly significant (P<0.001).  
APO NPO
54.50%
45.50%
24.60%
75.40%
Comparison of Perinatatal outcome between  HELLP 
and non HELLP 
HELLP Non-HELLP
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Table: 20.Comparison of Perinatal outcome between HELLP and non 
HELLP    
Foetus 
condition 
HELLP 
Non-
HELLP 
Total 
χ2 df Significance 
No % No % No % 
IUD 12 27.3 4 7.0 16 15.8 
7.642 1 P<0.01 Alive 32 72.7 53 93.0 85 84.2 
Total 44 100.0 57 100.0 101 100.0 
 
72.7% of babies among HELLP group were alive and 93% of babies among 
Non-HELLP group were alive. 27% were IUD among HELLP group and 7% 
among Non-HELLP group. Hence IUD is strongly associated with HELLP 
syndrome. 
  
IUD Alive
27.30%
72.70%
7%
93.00%
Comparison of Perinatatal outcome between  
HELLP and non HELLP   
HELLP Non-HELLP
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Table:21. Comparison of birth weight of babies between HELLP and non 
HELLP:    
Variable HELLP, 
n=44 
Non HELLP, 
n=57 
Difference 
b/w 
means 
‘t’ df Significance 
Mean SD Mean SD 
birth 
weight 
1.9 0.7 2.2 0.6 0.3 2.064 99 P<0.05 
 
The mean birth weight of babies belonging to HELLP mothers was 1.9±0.7 
Kg. The same of the non HELLP group mothers was 2.2±0.6 Kg. The different in 
the mean birth weights between the two groups was statistically significant 
(P<0.05). 
Table:22 Treatment Regimen 
 ANTI HYPERTENSIVES 
+ MGSO4 REGIMEN 
ANTIHYPERTENSIVES 
ONLY 
No. of cases 34 9 
Percentage 79.0% 20.9% 
 
79%
21%
Treatment Regimen
ANTI HYPERTENSIVES + MGSO4 REGIMEN
ANTIHYPERTENSIVES ONLY
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Table:23 ADMISSION – DELIVERY INTERVAL IN HELLP 
SYNDROME  
< 6 hrs 6-10 hrs 11-15  hrs 
5 30 8 
11.6% 69.7% 18.6% 
 
  
11%
70%
19%
ADMISSION – DELIVERY INTERVAL IN HELLP SYNDROME 
< 6 hrs 6-10 hrs 11-15 hrs
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I   ANALYSIS OF MATERNAL MORTALITY  
a. AGE 
20-24 25-29 30  and above 
2 - 3 
40% - 60% 
b. GRAVIDA 
Primi Multi 
2 3 
40% 60% 
c. BLOOD PRESSURE 
SEVERE PRE ECLAMPSIA ECLAMPISA 
4 1 
80% 20% 
d. GESTATIONAL AGE 
28-30weeks 31-34 weeks 
1 4 
20% 80% 
e. PROTEINURIA 
++ +++ ++++ 
1 3 1 
20% 60% 20% 
f. PLATELETS COUNT 
CLASS I < 
50,000 
CLASS II 50,000 - 
1,00,000 
CLASS III 1,00,000 - 
1,50,000 
3 2 - 
60% 40% - 
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g. LDH  
Case LDH Level IU/L 
1.  2242 
2.  2774 
3.  3000 
4.  4000 
5.  3686 
All cases were between 2000-4000 IU/L 
h. SGOT & SGPT 
Cases SGOT  SGPT 
1.  114 96 
2.  185 456 
3.  176 576 
4.  261 265 
5.  256 254 
There is high level of SGOT & SGPT in HELLP syndrome. 
i. MODE OF DELIVERY 
All patients delivered by LSCS.  
j. ADMISSION-DELIVERY-DEATH INTERVAL 
24 hrs 48 hrs 
3 2 
60% 40% 
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k. MATERNAL MORTALITY - CAUSES  
ACUTE RENAL 
FAILURE WITH 
DIC 
ABRUPTION WITH 
DIC 
ABRUPTION 
WITH 
PULMONARY 
EDEMA 
2 2 1 
40% 40% 20% 
 
According to Table a-k, there were 5 cases of death in HELLP syndrome 
giving rise to maternal mortality rate of 11.6%. 40% were primi between 20-
24 years of age, and 60% were multi between 30-35 years of age mostly in 
severe preeclampsia at 30-34 weeks gestation. All cases had significant 
proteinuria, delivered within 15 hrs of admission. Most common causes of 
death were abruption and acute renal failure. 
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CONSOLIDATED ANALYSIS OF THE STUDY 
STUDY HELLP 
SYNDROME 
NON- HELLP 
SYNDROME 
Total No. of cases  43 57 
Proteinuria  ALL ALL 
Fundus Changes 7 10 
Low plateletcount 43 - 
Evidence of haemolysis 43 - 
Elevated liver enzymes  43 - 
Mode of Delivery    
LN 24 25 
Forceps  1 2 
LSCS 18 30 
Fetal outcome  12  
IUD 4 
Alive  32 53 
Preterm  36 37 
Term 7 20 
Maternal outcome    
No complication 22 45 
Abruption  9 6 
ARF 7 2 
CVT 1 1 
Cerebral edema 1 1 
Pleural effusion   1 1 
Sepsis  1 0 
Pulmonary edema 1 0 
 HELLP  
SYNDROME  
 Alive  38 37 
Expired 5 0 
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CONSOLIDATED INFERENCE OF THE STUDY 
Total no. of cases studied : 100 
Proteinuria : 
All 
(100%) 
Fundus changes : 17 (17%) 
Low platelets count : 43% 
Elevated liver enzymes   : 43% 
Evidence of haemolysis  
MODE OF DELIVERY 
: 43% 
LN : 49 (49%) 
Forceps : 3 (3%) 
LSCS : 48 (48%) 
 
MATERNAL OUTCOME 
Abruption : 1 (15%) 
Acute Renal failure  : 9 (9%) 
CVT : 2 (2%) 
Cerebral edema : 2 (2%) 
Sepsis : 1 (1%) 
Pulmonary edema  : 1 (1%) 
Pleural effusion  : 2 (2%) 
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PERINATAL OUTCOME 
IUD  : 16 (16%) 
Alive             : 85 (85%) 
Preterm  : 73 (73%) 
Term : 27 (27%) 
MATERNAL MORTALITY  
IN HELLP SYNDROME                       : 5 (11.6%) 
 
PERINATAL MORTALITY  
IN HELLP SYNDROME                : 24 (54.5%)  
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DISCUSSION 
A study of 100 cases of HELLP syndrome and non-HELLP syndrome 
was undertaken during the year 2015 for a period of six months and the result 
were compared between the economic, demographic, physiological, 
biochemical, and obstetric character. 
Incidence  
James N.Martin 4-12% 
B.E. Reubnoff 12-13.6% 
Sibai 1986 9.7% 
Sibai & Mohammed 1993 18.9% 
My study   17.6% 
The wide range of incidence can be attributed to the remarkable 
variability of the diagnostic criteria of the syndrome. In addition, these 
incidence rates cannot be considered for general population since they are 
reported from tertiary referral centres  
Age 
 University of Tennessee, Memphis 24.4 years 
 English literature    24.9 years 
 My study     25.2 years 
Gravida 
 B.E. Reubinoff (1990)   Multi 
 My study     Multi (55.8%) 
High incidence of HELLP Syndrome in multi (55.8%)  
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Socioeconomic status  
All cases belong to low socioeconomic status probably because our 
institution caters of mainly to economically deprived strata of society. 
Gestational age 
The average, gestational age at presentation is 33.8 weeks, 70% of 
HELLP Syndrome patients manifest before labour, while 30% manifest after 
delivery. According to Sibai 82% cases developed HELLP syndrome at <37 
weeks. According to my study average gestational age at presentation is 33.2 
weeks, HELLP syndrome manifest mostly during antepartum. 
Clinical Symptoms & Signs 
The frequent symptom is epigastric pain and /or right upper quadrant 
pain (90%) accompanied by nausea and vomiting. Headache may be present in 
50% cases. In my study 40% cases had Headache associated with nausea and 
vomiting, rest of the patients (60%) with Oliguria, Nausea, Vomiting and 
convulsion. 
Blood pressure 
 Severe pre eclampsia Eclampsia 
Sibai et al 30% 10% 
B.E. Reubinoff  
1991 
67% - 
My study 90.7% 9.3% 
According to my study, 90% HELLP syndrome was associated with 
severe preeclampsia and 9.3% belonged to eclampsia.  
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Proteinuria 
Urine analysis showed proteinuria of more than 2+ in 95.3% cases of 
HELLP Syndrome. It should be emphasized that 15% of HELLP Syndrome 
patients present with neither hypertension nor significant proteinuria (B.E. 
Reubinoff et al) In my study 4.7% patients had 1+ poteinuria, 30.2% had 2+ 
proteinuria, 48.8% had 3 + proteinuria and 16.3% had 4+ proteinuria. 
According to Sibai, some women with HELLP Syndrome however 
hypertension and proteinuria may be absent or slight. Thus it is imperative that 
all health care providers become knowledgeable about clinical signs & 
symptoms that might herald the onset of HELLP Syndrome. 
Platelets levels in HELLP Syndrome 
 Class I Class II Class III 
Martin 1990 1.09% 28% 71% 
My study 30.2% 55.8% 14% 
The definition of abnormal level varies among different studies. 
Severity of HELLP Syndrome is reflected in its laboratory parameters and not 
in the usual clinical parameters like blood pressure and proteinuria. 
Haemolysis   
Although microangiopathic hemolytic anemia underlies HELLP 
Syndrome, paradoxically most patients are not anemic when first admitted to 
the hospital. In my study all 43 cases had hemolytic blood picture with mean 
haemoglobin level of  7.8 gms ± 2.5g%. 
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Liver enzymes  
According to B.E. Reubinoff et al., type of enzymes and definition of 
abnormal level also varies among different studies. There is direct correlation 
between the degree of thrombocytopenia and measures of liver dysfunction. 
An inverse correlation between platelets and LDH concentration was seen in 
both classes of HELLP Syndrome. Serum concentration of SGOT generally 
paralleled lactate dehydrogenase during the course of HELLP Syndrome. In 
my study there is inverse correlation between platelets and LDH in HELLP 
Syndrome. 
Fundus Changes  
In my study 7 cases of HELLP Syndrome had evidence of vasospasm 
and disc hyperemia at fundus examination (15.3%) 
Treatment regimen  
79% cases were started on MgSO4 regimen in addition to 
antihypertensive, while 20.9% cases were in antihypertensive only. 
Mode of delivery 
According to Sibai (1999), caesarean delivery rate is high with HELLP 
Syndrome especially when pregnancy is less than 34 weeks of gestation (68%). 
In pregnancies less than 30 weeks of gestation caesarean section rate is 87%. 
According to my study, 55.8% cases of HELLP Syndrome delivered by Labour 
natural, 41.9% by LSCS 2.3% by Forceps. 
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Admission Delivery interval 
According to Martin (1990) Length of time between hospital admission 
and delivery with a mean of 15.6 hours. According to my study admission 
delivery interval was less than 15 hours in all cases of HELLP Syndrome. 
Maternal Outcome  
Though coagulapathy has been mentioned as the most common 
complication of HELLP Syndrome, in my study all parameters like bleeding 
time (B.T), Clotting time (C.T), serum fibrinogen were normal. This may be 
due to non-sensitive parameters to detect DIC. More sensitive parameters like 
antithrombin IV, factor VIII and D-dimer may be needed to detect DIC. 
 Abruption Renal failure Cerebral edema  
Sibai 1999 20% 8% 1% 
My study 20.9% 16.2% 2.3% 
 
Maternal Mortality 
According to sibai (1999) incidence of maternal mortality is as high as 
24%. In my study, there were 5 cases of maternal death giving rise to maternal 
mortality rate of 11.6%, of these 1 case was due to Pulmonary edema with 
abruption 20%, 2 case was due to abruption and DIC 40% and 2 case was due 
to ARF with DIC 40%. 
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Analysis of maternal mortality  
2 cases were in 20-25 years of age and 3 cases were in 30-35 years of age  
Gravida - 2 cases were primigravida and 3 case were multigravida 
Blood pressure-80% cases belong to severe preeclampsia, 20% cases 
belong to Eclampsia.  
Gestational age - 4 cases were in 30-34 weeks and 1 case was in 28 
weeks. 
Proteinuria - All 5 patients had ≥ 2+proteinuria.  
Platelet count - 40% cases belong to class-II and 60% cases belongs to 
class-I HELLP Syndrome. 
Liver enzymes - SGOT, SGPT and LDH were significantly elevated in 
all 5 cases. 
Mode of delivery – All delivered by LSCS. 
Admission - delivery death interval - 1 day for 3 cases (60%) and 2 days 
for 2 case (40%) In spite of early delivery there was 5 deaths in my study, 
probably due to late referral. 
Perinatal outcome 
According to Sibai perinatal mortality is 30-40% primarily because of 
prematurity. There is a significant trend for advanced form of HELLP 
Syndrome (Class I & Class II) to appear at earlier gestational age. According 
to my study perinatal mortality is 54.5% primarily of prematurity. 
Sibai 1999            30-40% 
My study             54.5% 
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Birth weight of the baby 
According to English literature, average weight of the new born is 1524-
1898 gms and 30% were small for gestational age. According to my study the 
birth weight of live born babies of HELLP syndrome mothers significantly 
lesser than the non-HELLP syndrome babies. Mean birth weight of babies of 
HELLP mothers was 1.9 ± 0.7 kg. 
Post-partum period 
Lowest platelet count did not predict peak values of aspartate 
aminotransferase or lactate dehydrogenase. The degree of abnormality of 
platelet counts, AST and LDH did not perspectively and accurately predict time 
of recovery. According to text, at 5-7 days after delivery, platelet count were 
above 1,00,000/cumm in 85-96% of cases, AST were below 70 IU/L in 85-
96% and LDH values were below 600 IU/L in 76-89%. In my study all cases 
for platelet count and liver enzymes reverted to normal levels by  4th – 7th  post 
partum day. 
1. The Hb level was significantly lesser among the HELLP syndrome 
mothers than their counter part non HELLP mothers. 
2. The SB-T, D, and I were significantly more among the HELLP 
syndrome mothers than the non HELLP mothers. 
3. Significant proteinuria is present in HELLP syndrome  
4. The incidence of HELLP syndrome is significantly more among Multi 
gravida. 
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5. Gestational age of HELLP syndrome was significantly lesser than the 
non HELLP. 
6. The SGOT, SGPT and LDH were significantly greater in HELLP group 
than the non HELLP group and Platelet count was significantly lesser 
in HELLP group than the non HELLP group.  
7. HELLP syndrome more commonly occurs in preeclamptic patient  
8. Mode of delivery was not significantly altered between both groups. 
9. The blood transfusion was significantly essential to HELLP syndrome 
subjects. 
10. The complications (48.8%) were significantly more among the HELLP 
group than the others. 
11. The mortality incidence (11.6%) was significantly more among HELLP 
group. 
12. The birth weight of live born babies of HELLP syndrome is 1.9 was 
significantly lesser than the other babies’ birth weight. 
13. 27.3% of IUD and 54.5% of abnormal prenatal outcome was strongly 
associated with HELLP syndrome. 
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SUMMARY 
The HELLP syndrome and non-HELLP syndrome were compared and 
analysed for a period of six months from Feb2015 to July2015 and the 
summary is as follows.  
Multigravida has a slightly higher incidence (55.8%) than primi. 
Mean maternal age of HELLP Syndrome as per this study is 22.2 years. 
Average gestational age that HELLP Syndrome presents is 33.2 weeks. 
Most cases of HELLP Syndrome occurred during antepartum  
Most cases of HELLP Syndrome belonged to severe preeclamptic group 
(90.7%) 
95.3% cases of HELLP Syndrome had ≥ 2+ proteinuria. 
30.2% cases of HELLP Syndrome belonged to class I, 55.8% cases 
of HELLP Syndrome belonged to class II and 14% cases belonged to class 
III HELLP Syndrome. 
Mode of delivery - 58.1% cases of HELLP Syndrome delivered by 
labour natural, 41.9% by LSCS, 2.3% by forceps. 
Admission delivery interval was <15 hours in all cases. 
Significant maternal morbidity in HELLP Syndrome was due to 
abruption(20.9%) and acute renal failure (16.2%). Significant peritnatal 
morbidity and mortality in HELLP Syndrome was due to prematurity. Maternal 
mortality rate in HELLP Syndrome is 11.6% Perinatal Mortality rate in HELLP 
Syndrome is 54.5%. In all cases, the laboratory parameters returned to normal 
limits within 4th – 7th postpartum day. 
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CONCLUSION 
The question of whether HELLP Syndrome exists as a distrint entity or 
not is a part of a spectrum of pregnancy complications, which have common 
liver dysfunction, haemolysis and thrombocytopenia has long been a source of 
speculation among obstetricians and physicians. However, the importance of 
this collection of signs and symptoms lies not in its name but rather in its 
associated high maternal and perinatal morbidity and mortality. Hence, 
1. Patient with HELLP Syndrome warrants an emergency obstetric help. 
2. HELLP Syndrome demands, careful and close evaluation of maternal 
and neonatal parameters and should be given equal attention in decision 
making. 
3. Prompt delivery is mandatory regardless of gestational age. 
4. Successful management requires recognition, a timely intervention and 
to render optimal patient treatment.  
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PROFORMA 
1. Name of the patient : 
2. Age : 
3. DOA : 
4. D.O.D. : 
5. IP No : 
6. Socio Economic Group : 
7. Gravida : 
8. Para : 
9. Abortion  : 10. L.M.P. : 
11. EDD : 
12. Past H/o. : 
13. F/H HT : 
Cardiac disease: 
 D.M : 
14. Present illness : 
a. Nausea / Vomiting  : 
b. Oliguria : 
c. Blurring in Vision : 
d. Head Ache : 
e. Epi gastric pain : 
f. Convulsion : 
15. G/E 
108 
a. Anaemia : 
b. Oedema : 
c. Pulse : 
d. BP : 
e. CVS : 
f. RS: 
16. O/E 
a. Ascites : 
b. Any overdistension : 
c. Height of uterus : 
d. Head engaged (or) not : 
e. F.H. : 
f. Amount of liquor : 
g. Abnormal Presentation : 
h. Complication Abruption : 
17. Investigations 
a. Daily weight : 
b. Haemoglobin  : 
c. Albumin Urine : 
 d  Fundus examination : 
e. Blood Urea : 
f. Sr.Uric Acid : 
g. Sr.Creatinine : 
109 
h. Coagulation profile : 
1 PT  : 
2 aPTT : 
3 Fibrinogen : 
i. Peripheral Smear : 
1 anisocytosis :  
2 Poikilocytosis :  
3 Schistocytosis :  
4 Burr Cells : 
5 Micro Spherocyte  
j. Serum Bilirubin : 
Total Bilirubin : 
Direct Bilirubin : 
k. SGOT : 
SGPT : 
Sr. LDH : 
l. Platelet count : 
m. USG : 
18. Management  : 
a Control of BP with Anti HT 
b Prevention of seizure with Inj. MgSo4: 
c Haemotheraphy   : 
i PCT : 
110 
ii Platelet : 
iii FFP : 
iv Cryo : 
d Induction / Augmentation 
19. Outcome of delivery : 
 Mode of delivery : 
a. Natural delivery : : 
b. Forceps : 
c. L.S.C.S. : 
20. Perinatal putcome 
a Alive / Still born / IUD 
b Term / Preterm  
c Birth Wt. 
d Apgar   
ABBREVATION 
1. SGOT - Aspartate Transaminase 
2. SGPT - Alanine Transaminase 
3. H - Head ache 
4. C - Convulsion 
5. V - Vomiting  
6. UO - Reduced Urinary Output 
7. N - Normal  
8. M -Multigravida    
9. P - Primigravida 
10. PE - Preeclampsia  
11. E - Eclampsia 
12. AP - Ante Partum Eclampsia 
13. IP - Intra Partum Eclampsia 
14. PP - Post Partum Eclampsia 
15. B - Blurring of Vision 
16. HU - Haematuria 
17. Wgt - Weight  
18. SYM - Symptom  
19. GA - Gestational Age 
20. BP - Blood Pressure  
21. BU - Blood Urea  
22. SC - Serum Creatinine  
23. UA - Uric Acid 
24. Urine ALB - Urine Albumin  
25. HB - Haemoglobin  
26. SrBil - T - Serum Bilirubin -  Total 
27. D - Direct  
28. I - Indirect  
29. LDH - Lactate Dehydrogenase  
30. PLT - Platelet  
31. PS - Peripheral Smear  
32.  MOD -  Mode of Delivery 
33. BT/Pdt - Blood Transfusion / Product  
34. COMPLI - Complication  
35. T/PT - Term / Preterm  
36. APG at 1mt - Apgar at 1mt 
37. MO - Maternal outcome  
38. PO - Perinatal outcome 
39. NPO - Normal Perinatal outcome 
40.  APO - Abnormal Perinatal outcome 
41. CVT - Cortical vein Thrombosis  
42. PUL Edema - Pulmonary Edema 
43. Plu effusion - Plueral effusion  
44. HD - Hemodialysis  
45. DIC - Disseminated intra Vascular Coagulopathy  
46. MODS - Multiple Organ Dysfunction Syndrome  
47. NHBP - Normal Haemogram Blood Picture  
48. OBSCODE - Obstetric Code  
49. IUD - Intra uterine death  
50. AFI - Amniotic fluid index. 
51. EGA - Estimated gestational age 
52. 𝑆𝑎𝑂2 - Oxygen saturation. 
53. PLGF - Placental growth factor  
54. HLA-C - Human Leukocyte Antigen – C 
55. INF - Interferon  
56. TGF - Transforming growth factor  
57. VEGF - Vascular Endothelial Growth Factor  
 
T D I
1 Jebaseela 19 30980 IV P N AP      37 C 60 160/110 32 0.9 5 ++ 11.4 0.4 0.2 0.2 21 23 216 302000 Non HELLP      NHBP LSCS - T 2.16 7/10 WELL NPO
2 Amudha 24 27405 V M N PE      36 H 59 140/90 29 0.6 3.9 + 6.5 1.9 0.9 1 107 86 680 66000 HELLP          Burrcells LN PCT T 2.75 8/10 WELL NPO
3
Sayed Ali Fathima 26 26919 III M N PE      34 H 65 170/120 16 0.7 2.1 + 12.1 0.8 0.4 0.4 26 13 175 230000 Non HELLP      NHBP LSCS - PT 2.4
7/10
WELL NPO
4 Mari 19 28183 V P N PE      36 V 66 140/90 19 0.6 3.2 ++ 8.9 4.1 1.3 2.8 85 112 595 49000 HELLP          Schistocytes LSCS PCT/Pdt PT 2.8 8/10 WELL NPO
5 Jebaselvi 20 29256 IV P N PE      37 H 61 180/130 16 0.6 4.5 + 12.7 0.4 0.2 0.2 26 36 195 185000 Non HELLP      NHBP LSCS - T 2.25 7/10 WELL NPO
6
Malathi 20 29128 V P G-I PE      38 C/B 55 190/90 16 0.6 4.4 +++ 10.6 0.7 0.4 0.3 55 65 701 88000 HELLP          fragmented RBCs LSCS PCT
Abruption / 
CVT PT 2.6
6/10
WELL APO
7
Pandichelvi 23 7648 V M N PE      35 HU 56 180/130 23 1.2 7.1 +++ 6.6 2.9 1.5 1.4 67 142 2500 34000 HELLP          Schistocytes LN PCT/Pdt DIC/ Pul Edema IUD 2.7
 -IUD
WELL APO
8 Sahith Mary 32 8626 V P N AP      34 H/C 54 150/90 26 0.8 5.3 +++ 11.1 0.8 0.4 0.4 37 23 356 212000 Non HELLP      NHBP LSCS - CVT PT 2.1 7/10 WELL NPO
9 Kani 20 7596 IV P N AP      35 C 58 130/90 17 1 4.2 +++ 4.6 1.2 0.8 0.4 40 38 285 230000 Non HELLP      NHBP LSCS PCT Plu effusion PT 2.5 7/10 WELL NPO
10 Sugapriya 27 6876 V P N AP      30 C 52 170/110 16 0.9 7.1 ++ 12 1.0 0.5 0.5 80 75 182 92000 HELLP          NHBP LN PCT PT 0.9 4/10 WELL APO
11 Mahalakshmi 23 6721 III M N PE      34 V 54 150/100 20 0.9 7.9 +++ 5.4 1.6 0.6 1 112 126 3396 48000 HELLP          Schistocytes LN PCT/Pdt PT 2.4 7/10 WELL NPO
12 Angalaeswari 29 26947 V P N PE      32 V 58 160/110 18 0.6 6 ++ 11 1.6 0.6 1 13 28 156 250000 Non HELLP      NHBP LN - PT 1.6 5/10 WELL APO
13 Muthulakshmi 25 26606 IV P N PE      37 ↓UO 52 156/110 33 2.5 7.9 +++ 8 0.6 0.3 0.3 84 75 2115 86000 HELLP          Schistocytes LN PCT ARF T 3 8/10 WELL NPO
14 Lakshmi 32 13488 IV P N PE      28 H/V 55 180/120 16 7 7 ++++ 12.6 1.6 0.4 1.2 107 122 779 90000 HELLP          burrcells LN - - PT 1 4/10 WELL APO
15 Tavampettral 34 13922 V M N PE      36 - 57 100/110 18 1.1 5.2 ++ 10.4 0.6 0.3 0.3 23 18 564 186000 Non HELLP      NHBP LSCS - - PT 2.4 7/10 WELL NPO
16 Mahalakshmi 23 8690 III M G-I PE      36 ↓UO 50 160/120 23 1.2 7.9 +++ 4.8 1.6 0.6 1 186 106 3396 51000 HELLP          Schistocytes LN PCT/Pdt PT 2.4 5/10 WELL APO
17 Revathi 25 8430 V P N PE      36 ↓UO 59 150/110 20 0.8 6 ++ 11.6 0.8 0.4 0.4 26 20 452 201000 Non HELLP      NHBP LSCS - - PT 2.6 8/10 WELL NPO
18 Rama 26 10297 IV P N PE      34 - 54 160/120 15 9 9.9 +++ 9.87 0.6 0.2 0.4 18 12 457 268000 Non HELLP      NHBP LSCS - - PT 2.1 7/10 WELL NPO
19 Ulagammal 22 12954 V P G-I PE      37 H/B 59 190/130 22 0.8 ++++ 7 1.0 0.5 0.5 102 95 2123 79800 HELLP          Schistocytes LSCS PCT/Pdt Abruption PT 2.9 8/10 WELL NPO
20 Vijayalakshmi 20 18477 V P N PE      35 C 60 200/120 23 0.9 9 ++++ 8 1.6 0.4 1.2 65 93 705 52000 HELLP          burrcells LSCS PCT/Pdt Abruption PT 2.4 6/10 WELL NPO
21 Jothimalar 27 17367 I V M N PE      36 ↓UO 55 180/130 27 0.7 3.7 ++ 6.5 0.7 0.4 0.3 36 30 490 320000 Non HELLP      NHBP LN PCT - PT 2.25 6/10 WELL NPO
22 Chellammal 20 16628 IV P N PE      29 H 54 160/110 18 1.1 2.8 ++ 8.4 0.5 0.3 0.2 40 20 286 220000 Non HELLP      NHBP LN PCT - PT 1 3/10 WELL APO
23 Umayaparvathi 22 16234 V P N AP      38 C 56 170/140 16 7 2.6 ++ 10.3 0.6 0.3 0.3 36 37 175 272000 Non HELLP      NHBP LSCS - PRESS T 3 8/10 WELL NPO
24
Iyyammal 20 21734 III P N AP      38 C 60 180/120 21 9 7 ++ 1.4 0.5 0.2 0.3 40 32 318 250000 Non HELLP      NHBP LSCS -
Abruption / 
CVT T 3.4
7/10
WELL NPO
25 Angel 25 31625 IV P N PE      30 H 54 180/110 38 1.2 8.6 +++ 7.6 2.4 0.6 1.8 93 105 920 67000 HELLP          fragmentedRBCs LN PCT/Pdt ARF PT 1.3  -IUD WELL/HDAPO
26 Noornisha 26 31259 V P N PE      29 ↓UO 55 150/110 62 2.9 9.9 ++++ 9 0.4 0.2 0.2 30 15 750 92000 HELLP          burrcells LN PCT ARF PT 1.2  -IUD WELL/HDAPO
27 Uma maheswari 27 14065 IV P N PE      36 - 59 170/130 16 1 3.6 ++ 11.8 0.4 0.2 0.2 29 16 551 350000 Non HELLP      NHBP LSCS - - PT 2 7/10 WELL NPO
28
mariyammal 29 16947 V P N PE      28 - 60 180/120 19 1.1 7.1 +++ 6.7 0.5 0.2 0.3 120 102 2680 85000 HELLP          Schistocytes LN PCT/Pdt
Abruption / 
CVT PT 1.2
 -IUD
WELL APO
29 Kadaleswari 21 19721 V M N PE      34 ↓UO 53 150/110 28 1.4 ++ 8.8 1.3 0.5 0.8 96 92 810 70000 HELLP          Schistocytes LSCS PCT/Pdt Plu effusion PT 18 6/10 WELL NPO
30 Santhanamari 25 9860 IV P N PE      28 H 36 190/110 28 0.8 7.2 + 13.3 0.8 0.4 0.4 170 112 175 41000 HELLP          fragmentedRBCs LSCS PCT/Pdt - PT 1.1 5/10 WELL APO
31 mallika 24 9620 V M N PE      32 H 58 140/110 37 1.2 8.3 ++ 12 0.5 0.3 0.2 68 46 652 120000 HELLP          NHBP LN - - PT 1.6 6/10 WELL NPO
32 Vasanthi 32 9919 V P N PE      36 - 57 150/100 18 0.7 12.6 ++ 12.6 1.0 0.6 0.4 38 22 160 285000 Non HELLP      NHBP LSCS - - PT 2.1 7/10 WELL NPO
33 maari 29 8875 V M N PE      30 H 58 170/100 18 0.9 6.8 + 10.3 1.0 0.5 0.5 57 72 450 156000 Non HELLP      NHBP LN - PT 1.4 4/10 WELL APO
34 Maheswari 23 9533 V M N PE      36 - 56 150/110 17 1 6.2 +++ 8.4 1.9 0.9 1 76 89 1675 45000 HELLP          fragmentedRBCs LN PCT/Pdt Abruption PT 2.2 6/10 WELL NPO
35 kaleswari 25 10086 IV P N AP      37 C 57 170/110 16 0.7 7.1 +++ 9 1.7 0.7 1 61 70 640 249000 Non HELLP      NHBP LSCS - - T 2.6 7/10 WELL NPO
36
angaleswari 24 10387 III M N PE      34 HU 58 140/100 17 0.6 6.8 +++ 6.4 2.5 0.9 1.6 92 88 4253 32000 HELLP          Schistocytes FORCEPS PCT/Pdt
Abruption / pul 
edema T 2.8
8/10
WELL NPO
37
marithai 23 22184 IV P N PE      34 - 56 170/100 19 0.6 8.8 ++ 8 2.9 0.2 2.7 96 115 1617 42000 HELLP          fragmentedRBCs LN PCT/Pdt
Abruption / 
sepsis PT 1.6
 -IUD
WELL APO
38 maliyammal 27 22780 V M N PE      28 H 53 170/100 2 0.8 3.8 +++ 12.6 1.6 0.8 0.8 40 14 897 103000 HELLP          burrcells LN - - PT 1 4/10 WELL APO
39 baby 2 10095 IV P N PE      37 - 49 150/100 18 0.7 4 ++ 8 0.6 0.3 0.3 31 27 872 187000 Non HELLP      burrcells FORCEPS PCT/Pdt - T 2.8 7/10 WELL NPO
40 esakkiyammal 21 9994 IV P N PE      36 - 53 170/110 16 0.8 7.2 ++ 11.8 0.6 0.3 0.3 29 11 584 264000 Non HELLP      NHBP LN - - PT 2.6 8/10 WELL NPO
41 megala 25 27790 IV P N PE      35 - 51 150/110 18 0.7 4.6 ++ 12.5 0.4 0.2 0.2 27 24 176 211000 Non HELLP      NHBP LN - - PT 2 8/10 WELL NPO
42 aruna saro 31 17154 III M N PE      32 H 70 190/130 40 3.1 9.2 +++ 7 6.0 3 3 114 96 2242 29000 HELLP          Schistocytes LSCS PCT/Pdt ARF / DIC PT 1.8 7/10 expired APO
43 aladi 30 20500 IV P N PE      38 - 62 140/100 16 0.6 6 ++ 14.4 1.7 0.7 1 30 70 620 99000 HELLP          fragmentedRBCs LSCS PCT/Pdt T 3 8/10 WELL NPO
44 rajam 33 25325 IV M N PE      28 V/H 58 180/120 33 1.7 8.8 ++ 8.7 5.2 2 3.2 185 456 2774 29080 HELLP          Schistocytes LSCS PCT/Pdt ARF / MODS PT 1  -IUD expired APO
45
bramaraj sanjana 35 11765 IV M G-II PE      30 B/H 76 220/140 56 3.2 10.3 ++++ 6.2 7.4 2.4 5 176 576 3000 89000 HELLP          Schistocytes LSCS PCT/Pdt
ARF / Pul 
edema PT 1.2
 -IUD
expired APO
46 pannerselvi 25 9671 IV P N PE      38 H 56 170/110 28 0.7 8.2 +++ 9 1.0 0.7 0.3 30 28 125 125000 Non HELLP      NHBP LSCS PCT T 3 8/10 WELL NPO
47 mumdaj 26 12430 V P N PE      32 H 60 160/120 20 0.6 6.2 +++ 6 0.8 0.6 0.2 116 118 195 105000 HELLP          NHBP LN PCT PT 1.7 7/10 WELL NPO
48 kanniyammal 19 11915 IV P N PE      28 V 50 160/120 26 0.7 7.8 +++ 9.2 0.9 0.6 0.3 28 28 278 110000 Non HELLP      NHBP LN - PT 1.1  -IUD WELL APO
49 pooma 23 18108 V P G-I PE      34 H/B 66 170/120 31 1.9 9 +++ 4 2.3 1.5 0.8 261 265 4000 40000 HELLP          Schistocytes LSCS PCT/Pdt ARF PT 2 2/10 expired APO
50 muthumari 26 21254 IV P N PE      38 - 66 170/120 28 0.8 8.4 +++ 9 0.9 0.7 0.2 39 36 388 270000 Non HELLP      NHBP LSCS - T 3.2 7/10 WELL NPO
51 valli 28 22294 IV P N PE      34 - 63 170/120 30 0.6 7.3 +++ 6.5 0.9 0.7 0.2 96 94 215 215000 Non HELLP      NHBP LN PCT PT 1.7 8/10 WELL NPO
PLT 
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3 
APG 
1mt 
MO POPS MOD BT / Pdt COMPLI T/PT
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52 zareena 23 25438 IV P G-I PE      36 H/B 55 180/120 68 1.4 7.5 ++++ 7.6 0.8 0.5 0.3 24 26 205 205000 Non HELLP      NHBP LSCS PCT ARF PT 1.6 3/10 WELL APO
53 kavitha 17 26077 V P N PE      38 H/V 60 170/120 30 0.7 7.6 +++ 9 0.9 0.6 0.3 82 86 195 180000 Non HELLP      NHBP LSCS PCT/Pdt Abruption T 1.9 6/10 WELL NPO
54 arumugam kani 27 2986 IV P G-I PE      28 - 60 180/120 24 1 7.3 ++++ 8.6 0.8 0.6 0.2 26 28 68 130000 Non HELLP      NHBP LN Abruption PT 1.1  -IUD WELL APO
55 brammachi 21 41158 IV P G-I PE      37 - 49 170/110 24 0.6 8 +++ 6.2 0.9 0.6 0.3 30 32 184 195000 Non HELLP      NHBP LSCS T 3.2 6/10 WELL NPO
56 anna selvi 18 23448 IV P G-II PE      36 - 51 150/120 23 0.7 6.8 +++ 9 0.9 0.6 0.3 152 146 668 115000 Non HELLP      burrcells LN PT 2.1 8/10 WELL NPO
57 lathamary 25 51389 V P N PE      36 - 52 160/110 28 0.6 8.2 +++ 6 0.8 0.5 0.3 22 24 118 205000 Non HELLP      NHBP LN PT 2.2 8/10 WELL NPO
58 niraimathi 31 9824 IV P N PE      36 - 66 170/110 38 0.6 7.3 +++ 9.2 0.9 0.6 0.3 36 34 194 115000 Non HELLP      NHBP LSCS PT 1.9 8/10 WELL NPO
59 thavamani 25 7038 V P N PE      37 - 53 160/110 28 0.6 7.8 +++ 10.1 0.9 0.6 0.3 20 28 107 135000 Non HELLP      NHBP LN T 2.4 8/10 WELL NPO
60 grace 23 23894 IV P N PE      36 - 49 170/120 28 0.6 8 +++ 11.6 0.8 0.5 0.3 26 28 148 142000 Non HELLP      NHBP LN PT 1.8 8/10 WELL NPO
61 kavipriya 21 29854 IV P G-II PE      28 - 58 170/140 22 0.7 7.1 ++++ 6.2 0.9 0.6 0.3 182 186 695 78000 HELLP          burrcells LN PCT/Pdt PT 0.8  -IUD WELL APO
62 mythili 28 34187 IV P N PE      37 - 61 180/130 32 0.8 7.9 +++ 8.6 0.8 0.5 0.3 91 93 212 165000 Non HELLP      NHBP LSCS T 2.8 8/10 WELL NPO
63 leemarose 23 44185 IV M N PE      36 - 59 170/120 33 1.4 9 +++ 7.2 2.0 0.7 1.3 253 172 1240 40000 HELLP          Schistocytes LSCS PCT sepsis T 2.1 7/10 WELL NPO
64 durgadevi 25 37288 V M N PE      36 58 140/110 26 0.8 3.2 +++ 5 1.1 0.5 0.6 230 115 1184 19000 HELLP          Schistocytes LSCS PCT/Pdt PT 2.5 7/10 WELL NPO
65 malathi 32 38305 IV M N PE      37 H 57 160/120 38 1.5 9 ++ 6 1.2 0.5 0.7 124 112 2292 47000 HELLP          Schistocytes LSCS PCT/Pdt CVT PT 3.2 7/10 WELL NPO
66 ushadevi 25 31873 IV M G-I PE      30 60 160/120 22 0.6 7.1 +++ 10 1.0 0.7 0.3 22 26 98 115000 Non HELLP      NHBP LN PT 1.2 7/10 WELL NPO
67 banu 19 28562 IV M N PE      37 H 62 170/110 28 0.6 8.2 +++ 9.2 0.9 0.6 0.3 94 90 611 105000 HELLP          burrcells LN T 1.8 7/10 WELL NPO
68 muneeswari 31 35010 V M GI PE      38 ↓UO 54 160/120 30 0.7 7.9 +++ 11.1 0.8 0.5 0.3 28 94 118 195000 Non HELLP      NHBP LSCS Abruption T 3.1 2/10 WELL APO
69 devi 22 40035 V M N PE      36 - 50 170/110 20 0.7 7 +++ 11.2 0.9 0.6 0.3 28 26 138 125000 Non HELLP      NHBP LN PT 1.8 8/10 WELL NPO
70 muppidathi 29 41095 IV M N PE      39 H/V 61 160/120 26 0.6 6.3 ++ 11.4 0.8 0.5 0.3 28 26 132 150000 Non HELLP      NHBP LN T 2 2/10 WELL APO
71 gomathi 20 52924 IV M N PE      34 V 47 170/110 30 0.7 6.8 +++ 10.6 0.9 0.6 0.3 30 28 184 110000 Non HELLP      NHBP LN PT 1.75 8/10 WELL NPO
72 ambika 28 46003 IV M N PE      32 H 52 150/110 23 0.6 7.6 +++ 6 2.8 1.6 1.2 124 128 1652 51000 HELLP          Schistocytes LN PCT PT 1.4 2/10 WELL APO
73 helen 31 52924 V M N PE      38 H 59 160/120 24 0.7 7.3 ++ 7 0.9 0.5 0.4 81 84 632 55000 HELLP          burrcells LSCS,TWINSPCT T 1.8,1.9 7/10 WELL NPO
74 vijaya 23 57882 V M G-II PE      28 H/V 55 150/120 20 0.7 7.3 +++ 11.4 0.8 0.6 0.2 30 28 154 230000 Non HELLP      NHBP LN - PT 1  -IUD WELL APO
75 kala 23 59023 V M N PE      34 - 49 120/100 26 0.6 7.2 +++ 5.2 0.9 0.6 0.3 84 86 620 70000 HELLP          burrcells LN PCT PT 2.2  -IUD WELL APO
76 kaliammal 31 61785 IV M N PE      34 - 54 120/110 26 0.6 6.8 +++ 8 0.9 0.6 0.3 34 32 124 170000 Non HELLP      NHBP LN PCT PT 1.7 8/10 WELL NPO
77 eswari 27 62951 IV M N PE      36 H 54 160/110 19 0.7 6.9 ++ 7.4 1.8 0.5 1.3 86 84 731 65000 HELLP          burrcells LN PCT/Pdt PT 1.8 2/10 WELL APO
78 krishnammal 25 6796 IV M G-I PE      38 - 58 170/120 28 0.6 6.8 ++ 8.2 1.0 0.7 0.3 20 28 176 195000 Non HELLP      NHBP FORCEPS PCT/Pdt T 3.3 8/10 WELL NPO
79 chitra 29 5836 V M N PE      32 H/V 62 160/120 18 0.7 6.5 +++ 4.8 0.9 0.6 0.3 102 110 1027 81000 HELLP          fragmentedRBCs LN PCT/Pdt PT 1.2 3/10 WELL APO
80 ananthi 18 18108 IV P N AP      28 H/C 56 160/120 18 0.7 6.4 ++++ 6.6 0.9 0.7 0.2 75 78 1652 85000 HELLP          fragmentedRBCs LN PCT PT 0.9  -IUD WELL APO
81
ammulakshmi 20 37985 IV P G-I AP      34 H/V 48 140/110 24 0.9 8.2 +++ 6 3.9 1.6 2.3 256 254 3686 75000 HELLP          burrcells LSCS PCT/Pdt Abruption / DIC PT 1.8
 -IUD
expired APO
82 ramalakshmi 24 7488 IV P N AP      28 H/V 66 150/100 22 0.6 7.1 +++ 10.4 0.8 0.5 0.3 24 24 162 165000 Non HELLP      NHBP LSCS - PT 0.85 1/10 WELL APO
83 vennila 31 4829 V M N AP      39 C 60 160/110 18 0.7 7.2 ++ 11.6 1.0 0.7 0.3 80 80 256 185000 Non HELLP      NHBP LSCS - T 2.7 8/10 WELL NPO
84 sakthi 22 2243 V M N PE      38 C 49 150/110 22 0.8 7.6 ++ 8.6 0.9 0.6 0.3 82 86 128 115000 HELLP          NHBP LN PCT T 2.6 8/10 WELL NPO
85 sumathi 22 28492 V M N AP      38 C 52 160/110 20 0.6 6.1 +++ 71.1 0.9 0.6 0.3 74 48 192 225000 Non HELLP      NHBP LSCS - T 2.8 7/10 WELL NPO
86 danalakshmi 23 31876 IV P N AP      34 C 56 150/110 22 0.7 6.4 +++ 10.6 0.9 0.7 0.2 18 19 112 115000 Non HELLP      NHBP LSCS - PT 2 7/10 WELL NPO
87 vadivu 24 49320 V M N AP      34 C 62 140/100 20 0.6 7.1 +++ 9.4 0.8 0.5 0.3 19 17 102 165000 Non HELLP      NHBP LSCS - PT 1.9 8/10 WELL NPO
88 rosey 20 56301 V P N AP      36 C 46 140/100 20 0.6 6.8 +++ 9.2 0.8 0.6 0.2 92 96 126 115000 HELLP          NHBP LSCS - PT 2.8 8/10 WELL NPO
89 mageswari 27 67925 V P G-I AP      30 C 50 150/110 22 0.7 7.1 ++ 9 0.9 0.6 0.3 20 21 140 125000 Non HELLP      NHBP LN - PT .1.4 2/10 WELL APO
90
sundarammal 31 58630 IV M N AP      28 C 59 160/100 18 0.6 7 ++ 5.1 3.9 1.6 2.3 98 112 1028 52000 HELLP          fragmentedRBCs LSCS PCT/Pdt cerebraledema PT 1.1
1/10
WELL APO
91
sowmiya 32 59023 V M N AP      34 C 63 140/110 22 0.7 7 +++ 7.4 0.9 0.6 0.3 19 22 96 140000 Non HELLP      NHBP LSCS PCT cerebraledema PT 2.1
7/10
WELL NPO
92 malar 23 2136 V P N AP      38 C 58 150/100 18 0.8 6.5 ++ 11.5 0.8 0.5 0.3 24 26 102 220000 Non HELLP      NHBP LSCS - T 3 8/10 WELL NPO
93 piriyanka 18 6023 IV P N PE      36 H/V 47 150/110 44 1.6 8 ++ 11.5 0.9 0.6 0.3 34 30 146 105000 Non HELLP      NHBP LN - ARF PT 2.1  -IUD WELL APO
94 rajeswari 22 3242 V M N PE      32 H 54 170/100 22 0.7 7 +++ 11.2 0.8 0.5 0.3 26 22 154 115000 Non HELLP      NHBP LN - PT 1.4 7/10 WELL NPO
95 buela 28 3949 V M N PE      37 V 65 150/100 24 0.6 3.7 ++ 6.4 0.8 0.5 0.3 20 24 126 126000 Non HELLP      NHBP LSCS PCT Abruption PT 2.9 8/10 WELL NPO
96 sangari 23 35186 IV P N PE      28 V 57 160/100 20 0.6 7.3 ++ 10.6 0.9 0.6 0.3 32 24 138 195000 Non HELLP      NHBP LN - PT 1.1 1/10 WELL APO
97 patturani 32 32018 IV M N PE      30 ↓UO /H 61 160/110 24 0.6 7.6 ++ 7.1 0.9 0.7 0.2 24 24 725 95000 HELLP          NHBP LN PCT/Pdt Abruption PT 0.9  IUD WELL APO
98 rathi 28 29870 V P N AP      32 H/C 61 170/90 28 0.6 9 +++ 11.4 0.8 0.5 0.3 28 30 185 310000 Non HELLP      NHBP LN - PT 1 3/10 WELL APO
99 muthu kani 30 41098 V M G-I PE      37 54 160/120 26 0.6 9.2 + 12 0.9 0.6 0.3 28 28 176 250000 Non HELLP      NHBP LSCS - T 2.5 8/10 WELL NPO
100 sorna 24 5229 V P N PE      34 H 60 160/110 32 0.7 8 ++ 10.8 0.9 0.6 0.3 24 22 202 210000 Non HELLP      NHBP LN - Abruption PT 1.7 8/10 WELL NPO
